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ABSTRACT  
   
Spinal muscular atrophy (SMA) is a neurodegenerative disease that results 
in the loss of lower body muscle function.  SMA is the second leading genetic 
cause of death in infants and arises from the loss of the Survival of Motor Neuron 
(SMN) protein.  SMN is produced by two genes, smn1 and smn2, that are 
identical with the exception of a C to T conversion in exon 7 of the smn2 gene.  
SMA patients lacking the smn1 gene, rely on smn2 for production of SMN.  Due 
to an alternative splicing event, smn2 primarily encodes a non-functional SMN 
lacking exon 7 (SMN D7) as well as a low amount of functional full-length SMN 
(SMN WT).  SMN WT is ubiquitously expressed in all cell types, and it remains 
unclear how low levels of SMN WT in motor neurons lead to motor neuron 
degradation and SMA.  SMN and its associated proteins, Gemin2-8 and Unrip, 
make up a large dynamic complex that functions to assemble ribonucleoproteins.  
The aim of this project was to characterize the interactions of the core 
SMN-Gemin2 complex, and to identify differences between SMN WT and SMN 
D7.  SMN and Gemin2 proteins were expressed, purified and characterized via 
size exclusion chromatography.  A stable N-terminal deleted Gemin2 protein 
(N45-G2) was characterized.   The SMN WT expression system was optimized 
resulting in a 10-fold increase of protein expression. Lastly, the oligomeric states 
of SMN and SMN bound to Gemin2 were determined. SMN WT formed a 
mixture of oligomeric states, while SMN D7 did not.  Both SMN WT and D7 
bound to Gemin2 with a one-to-one ratio forming a heterodimer and several 
higher-order oligomeric states.  The SMN WT-Gemin2 complex favored high 
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molecular weight oligomers whereas the SMN D7-Gemin2 complex formed low 
molecular weight oligomers. These results indicate that the SMA mutant protein, 
SMN D7, was still able to associate with Gemin2, but was not able to form 
higher-order oligomeric complexes. The observed multiple oligomerization states 
of SMN and SMN bound to Gemin2 may play a crucial role in regulating one or 
several functions of the SMN protein. The inability of SMN D7 to form higher-
order oligomers may inhibit or alter those functions leading to the SMA disease 
phenotype. 
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Chapter 1 
SMN PROTEIN AND SPINAL MUSCULAR ATROPHY 
1.1 Brief history of SMN and spinal muscular atrophy 
Both Micheal Lerner and Latchman (McAllister 1988, Sharpe 1989) 
discovered the Survival of Motor Neuron (SMN) Protein in the early 1980’s.   
Both scientists reported SMN to be a gene product that was involved in RNA 
splicing.  SMN was named Sm polypeptide N because of sequence similarities to 
the Sm class of proteins that function to assemble the splicing machinery 
(Schmaus 1989).  Six years later deletions and mutations in the smn gene were 
identified in patients with a disease called spinal muscular atrophy (SMA), a 
debilitating and fatal genetic disease that begins with lower motor neuron 
degeneration in the spinal cord followed by loss of muscle function in the trunk 
and lower body and eventually death (Levebre 1995).  Although, much has been 
uncovered in the last thirteen years about the detailed molecular function of SMN 
in splicing and other RNA processing events, the specific role of SMN in the 
pathology of SMA is still unknown and there are no treatments for the disease. 
1.2 Clinical Features of Spinal Muscular Atrophy   
 Spinal muscular atrophy (SMA) is an autosomal recessive disease that 
affects approximately 1 in 6000 infants and is the second leading genetic cause of 
death in children after cystic fibrosis.  A physician named Werndig (Levebre 
1995, Xiao 2011) reported neurological symptoms of SMA such as partial or total 
muscular atrophy of lower limbs and chest as early as 1891.  The muscle atrophy 
is preceded by the loss of function of the lower motor neurons called alpha motor 
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neurons, which are located in the anterior horn of the spinal cord.  Alpha motor 
neurons are composed of three main parts; the cell body located in the spinal cord, 
the axon that extends from the spinal cord to the muscle and the muscle fibers 
(Figure 1.1).  The function of alpha motor neurons is to send an electrical signal 
through the axons to the muscle fibers, which causes the muscles to contract.  The 
neuromuscular junction (NMJ) is located at the muscle-axon interface and is 
responsible for transducing the electrical signal across the synapse to the muscle 
fibers.  In SMA, motor neurons are shown to be non-functional, which was 
indicated by abnormal axon and NMJ composition relative to healthy motor 
neurons (Figure 1.1) (Baumer 2010).  The molecular mechanism that leads to the 
loss of function of alpha motor neurons in SMA is unknown. 
 
Figure 1.1- Motor Neurons and SMA 
Diagram of an alpha motor neuron showing the cell body (orange) located in the 
spinal cord connected to the axon (blue), which connects to the muscle fibers 
(red). The neuromuscular junction (NMJ) is located between the axon and the 
muscle.   
 
SMA is categorized into type I-IV with type I being the most severe and 
type IV being the least severe (Table 1.1).  Type I SMA patients have onset of 
disease symptoms in infancy, prior to 6 months of age.  Type I patients are never 
able to walk or sit up without assistance.  As the muscle failure progresses into the  
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diaphragm and trunk muscles.   The disease progresses rapidly as type I patients 
usually do not live past their second birthday.  Type II patients have a slightly 
later disease onset of 6-18 months and have less severe symptoms allowing them 
to sit up and sometimes walk.   The life expectancy of type II patients ranges from 
5-11yrs of age.  Type III SMA patients have a normal life expectancy and a rare 
type IV is characterized by an adolescent or adult disease onset (Xiao 2011,).  The 
symptoms of the less severe types III and IV are impairment of muscle function 
usually leading to use of a wheelchair (Xiao 2011).  Currently, physicians can 
only monitor the progression of the disease and help patients live a comfortable 
life with breathing, feeding and mobility assistance.   
 
Table 1.1- SMA disease types 
SMA has four disease types (I-IV) based on age of onset and severity of 
symptoms. 
 
Understanding how mutations in the SMA patient genotype lead to the 
SMA disease phenotype at a molecular level is crucial in the drug discovery 
process.  Identifying the molecular link of a disease requires two processes, 
determining the mutated gene product or protein produced from transcription and 
translation within the cell, and then determining how the mutated protein 
functions to cause the disease.  The atomic structure of proteins provides insight 
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into the molecular function.  Determining the differences in molecular function 
between native and mutant disease proteins provides potential drug targets that 
then allow for high-through put molecule screens or rational drug design to 
identify a successful drug.  A drug is defined as successful by its ability to 
specifically alter the molecular function of the disease protein, relieve the 
symptoms or underlying pathology of the disease and its level of safety for human 
consumption.  Consequently identifying a drug requires several costly rounds of 
trial and error to meet the above criteria.  Because the drug discovery process is 
risk intensive and expensive, more knowledge about the structure-function 
relationship and the molecular pathway of a mutant protein increases the 
probability and efficiency of creating a drug.   
1.3 Genetics of SMA 
SMA research has progressed rapidly in the last decade because of the 
dynamic increase and efficiency of gene sequencing and cellular imaging 
techniques.  These technologies have resulted in a broad picture of the genotype-
phenotype link in SMA. SMA patients have gene mutations that lead to reduced 
levels of full-length SMN protein, which cause cell death in the anterior motor 
neurons.  In humans, the two smn genes are located on a 500kb segment of the 
5q13 chromosome as two inverted copies, which resulted from a gene duplication 
event during evolution (Burglan 1995, Capon 1995, Lefebre 1995).  The smn1 
gene is located on the centromeric side of the chromosome, whereas smn2 is 
located on the telomeric side.  The two genes are identical in sequence with the 
exception a C to T conversion in exon 7 of smn2.  The T in exon 7 of smn2 causes 
  5 
an alternative splicing event after transcription that excludes exon 7.  Due to 
alternative splicing, smn2 is translated into 90 % of SMN lacking exon 7 
(SMND7) and 10% of full-length SMN (SMN WT) (Lorson 2000, Lorson 1999, 
Crawford 1996) (Figure1.2).   
  
Figure 1.2- Genetics of SMA 
SMN is produced from two genes, smn1 and smn2. The transcription and 
translation smn1 leads to full-length SMN (SMN WT shown in light blue circles). 
Due to a C to T conversion in exon seven (green) of smn2, an exon skipping event 
occurs producing primarily SMN lacking the region encoded by exon seven 
(SMN D7 shown in dark blue).  
 
Ninety-five percent of SMA patients have deletions in exon 6 of the smn1 
gene, which result in a C-terminal truncated protein that is ironically similar to the 
SMN D7 protein.  Another 5% of patients have missense mutations in the smn1 
gene, which also result in non-functional SMN protein (Levebre 1995, Thompson 
1995).  Because SMA patients do not produce full-length SMN protein or SMN 
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WT from the smn1 gene, they rely on the 10% of full-length SMN produced from 
the smn2 gene.  Although a small percentage of healthy people lack smn2, all 
SMA patients have a copy of the smn2 suggesting that the lack of any SMN WT 
production is embryonically lethal (Workman 2009).  The number of smn2 genes 
and the amount of full-length SMN WT protein produced in SMA patients is 
directly correlated to the severity of the SMA phenotype with type III patients 
having 3-4copies and thus more SMN WT, type II having 3 copies and type I 
having 2 copies (Mailman 2002,Wirth 2006).  SMN is expressed in all cell types; 
however, the mechanism by which low levels of SMN cause a phenotype only in 
motor neurons of SMA patients is unknown.   
1.4 SMN protein 
The smn gene contains nine exons, 1, 2a, 2b, and 3-8 that translate into a 
292 amino acid protein with an approximate molecular weight of 32kDa (Lui 
1997).  SMN has four domains, the K-rich domain, the P-rich domain, the Tudor 
domain and the YG domain (Burghes 2009) (Figure 1.3). The K-rich domain is 
encoded by exons 2a and 2b.  Exon 2a is important for binding to Gemin2 and 
exon 2b contains a self-association region (Young 2000).  The P-rich region 
includes exon 6 and part of exons 4 and 5 and is thought be important for 
profilin3 binding (Giesemann 1999).  SMN does not contain any apparent 
sequence homology to other proteins with the exception of the Tudor domain, 
amino acids 90-160, a conserved domain of unknown function originally 
discovered in drosophila (Buhlor 1999).  The Tudor domain located in exon 3 has 
a Sm protein like fold, which consists of a highly bent anti-parallel beta strand.  
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The Tudor domain interacts with splicosomal Sm proteins B, D1 and D3 and 
other RG rich proteins (Selenko 2001, Paushkin 2002).  The RG protein-Tudor 
domain interaction is enhanced by the di-methylation of the arganine residues and 
is most likely an important regulation step for the several identified RG proteins 
that bind the Tudor domain.   The C-terminal YG box domain contains a self-
association region that extends partially into exons 6 and 7 with a stronger affinity 
relative to the N-terminal self-association region encoded by exon 2b (Talbot 
2007, Young 2000).  It is postulated that the N and C terminal self-association 
domains interact to form a dimer or the relatively weaker exon 2 site could 
interact with other SMN proteins to promote oligomerization (Young 2000).  
Supporting the importance of these self-association interaction regions, SMND7 
lacking part of the self-association region has a decreased ability to self-associate 
and form oligomers, which disrupts the splicosomal assembly function of SMN. 
SMND7 and SMA missense mutants that are unable to form oligomers are 
unstable and rapidly degraded in vivo (Burnett 2008). Only 5% of SMA patients 
have missense mutations, and the majority of those are located in the self-
association region and the Tudor domain, with two occurring in the Gemin2 
binding region. The reduction in the self-association of SMN missense mutants 
correlates to SMA disease severity (Lorson 1998, Pellerzoni1999 ).  In SMA mice  
that have been engineered to express low levels of SMN WT,  expression of SMN 
D7 was able to oligomerize with SMN WT and partially rescue 
neurodegeneration defects (Le 2005).  SMA mutations in both the Tudor domain 
and C-terminus have been shown to inhibit Sm protein binding and other SMN 
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substrates such as nuclear proteins RNA pol I and GARI (Jones 2001, Pellizoni 
2001, Buhler 1999, Paushkin 2002).  Although much is known about the function 
of each domain of the SMN protein, little is known about the concerted molecular 
function of the SMN domains. 
 
Figure 1.3- SMN protein domains 
The SMN protein is encoded by 9 exons that contain the K-rich (red), Tudor 
(blue), P-rich (pink), and YG (black) domains.  Several regions of the protein 
(black boxes) have been associated with functions such as protein binding and 
self-association. 
 
1.5 The SMN complex 
SMN exists in a large a dynamic macromolecular complex containing 
Gemins2-8 and unrip proteins.  The SMN complex is a scaffold that assists in the 
assembly of ribonucleoproteins (RNPs) and localizes both to the cytoplasm and 
also to small foci in the nucleus called gems and coiled bodies (CBs) (Battle 
2006).  The function of CBs is unknown, but CBs contain the marker protein 
coilin, splicosomal RNP’s and other RNPs and are thought to function in RNA 
processing and RNP assembly.  Gems are often neighbors to CBs, but they do not 
contain coilin and are highly enriched with both the SMN complex and SnRNPs 
and may be a storage or recycling site for these complexes.  SMN along with 
Gemins 2-8 and Unrip are termed the SMN complex because of their stable 
association (Otter 2007) (Figure 1.4).  The SMN complex purified from Hela 
nuclear extracts is similar in size to the 20S ribosomal RNA complex, while 
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complexes purified from whole Hela cells range in size from 20S-80S (Meister 
2000, Carassimi 2006).    
 
 
Figure 1.4- The SMN complex 
The SMN complex is made up of SMN, Gemins 2-8 and Unrip. SMN interacts 
with Gemins2, 4 and 8. Gemin2 interacts with SMN, Gemins 5 and 7.  Gemin8 
interacts with SMN, Gemin6 and 4.  Gemin3 is associated to the complex via 
Gemin4. Unrip is associated with the complex via Gemin7. 
 
Gemin2, first characterized, as SMN interacting protein 1 (SIP1), does not 
have a clear role in the function of the SMN complex, but according to recent 
structural results, functions as a bridge between SMN and Sm proteins D1, D2, E, 
F, and G and may even regulate RNA-Sm protein interactions (Sarachan 2012, 
Zhang 2011). Gemin3, is a DEAD box protein, a class of RNA helicase proteins, 
which may be important in the RNA-protein assembly process (Lee 2005). Gemin 
4 associates with Gemin3 and has an unknown function, but includes a nuclear 
localization signal that may transport the SMN complex into the nucleus 
(Charroux 2000, Lorson 2008).  Gemin 5 is an RNA binding protein that 
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associates with the SMN complex through its interaction with Gemin2 and 
associates with snRNAs to recruit them to the SMN complex (Battle 2006).  
Gemins 6 and 7 form a heterodimer that surprisingly has a Sm-fold. The 
heterodimer is proposed to bind to the Sm heptamer in place of B and D3 in the 
snRNP assembly process (Leung 2005, Ma 2005).  Gemin8 and Unrip both have 
unknown functions (Grimmler 2005, Carissimi 2006).  As more of the 
components of the SMN complex have been discovered, the interactions between 
the proteins appear to be complex (Figure 1.3).  The evidence points to a myriad 
of dynamic and complex interactions that have not yet been correlated to the 
function of the SMN complex.  Adding to the complexity is the fact that several 
of the Gemin proteins and Unrip have SMN-independent functions such as DNA 
repair, virus replication, and even SMN is proposed to have functions independent 
of the SMN complex such as transcription regulation (Pellizzoni 2001, Hamamoto 
2006, Grimmler 2005, Moureletatos 2002).   
1.6 The SMN complex and splicing 
RNP’s are composed of non-coding RNAs and their associated proteins 
and they perform a variety of functions in the cell including processing and 
modification of ribosomal RNA (snoRNP’s), splicing (snRNP’s), mRNA 
processing, Histone mRNA  processing (U7snRNP) and telomere maintenance 
(Jones 2001, Pillai 2003, Bachand 2002,  Levebre 2002, Pellizoni 2002). The 
SMN complex is associated with each of the above RNPs; however, its role in 
assembling splicosomal snRNPs is the best understood.  The RNA component of  
splicosomal RNAs, uridine-rich small nuclear RNAs (snRNA) are transcribed in 
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the nucleus and transported to the cytoplasm where the SMN complex recognizes 
a specific code, the sm site (AUUUA), a sequence specific region 5’ and a non-
specific 7-12bp RNA stemloop usually at 3’ side of the sm site.  Gemin5 contains 
an RNA binding WD repeat that specifically recognizes and binds snRNAs.  The 
SMN complex recruits the seven heptameric Sm proteins (B, D1, D3, E, F and G) 
both through interactions of the SMN tudor domain (B, D1, and D3) and the 
Gemin proteins and deposits the ring in an ATP-dependent manner onto the 
snRNA (Meister 2001, Battle 2006) (Figure 1.5).  Once the Sm proteins are 
assembled, the exosome is able to trim the 3’ end of the RNA.  The RNA is then 
capped with a trimethylgaunasine, and re-imported back into the nucleus.  Inside 
the nucleus, snRNPs are directed to the Cajal bodies (CBs) to meet up with the 
last of the proteins required for snRNP function as well as receiving some final 
RNA modifications before being sent to the sites of transcription for pre-mRNA 
splicing (Eggert 2006, Workman 2012). 
 
 
Figure 1.5- The role of SMN in assembly splicing machinery 
The SMN complex chaperones the assembly of snRNPs. SMN first associates 
with the heptamer of Sm proteins and then recruits the snRNA. SMN assembles 
the Sm core onto the snRNA in an ATP-dependent manner. The snRNA 
undergoes RNA processing including trimming of the 3’ end. 
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1.7 Molecular mechanisms of SMA 
Because of SMN’s well-known role in splicing and the fact that low levels 
SMN do cause a decrease in Sm protein binding and splicing in the cell, the first 
proposed molecular mechanism that causes SMA is a defect in splicing.  In this 
case, the motor neurons in SMA patients due to deficient amounts of full-length 
SMN WT are theorized to be more sensitive to global splicing defects then other 
types of cells or a specific mRNA transcript in the motor neuron is affected by a 
splicing defect (Burghes 2009).  Because a specific or global splicing defect has 
yet to be revealed, other molecular mechanisms proposing a splicing-independent 
function have been investigated.  The observation that SMN and some Gemins, 
but not Sm proteins localize with β-actin mRNA at the growth cones of motor 
neurons and the SMN interaction with Hn-RNP-R that binds to b-actin mRNA led 
to the splicing-independent theory that SMN may be responsible for axonal 
transport of β-actin mRNA (Rossoll 2002, Rossoll 2009, Todd 2010a, Todd 
2010b). In the β-actin mechanism, SMA motor neurons have defects in the axon 
growth and axon growth cones of motor neurons because the β -actin mRNA 
cannot be transported to the growth cones.  More research into both the splicing 
and axonal transport mechanisms will likely determine the role if  each or even 
possibly both of these molecular events is involved in the pathogenesis of SMA 
(Fallini 2010). 
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1.8 Current therapies in SMA 
Without a full understanding of the complex molecular mechanism for 
SMA, current treatment avenues are focused on increasing the amount of SMN 
WT protein in SMA patients.  The first treatment approach is to use small 
molecules and antisense oligonucleotides (ASO’s) that inhibit the alternative 
splicing and exon seven exclusion of the smn2 pre-mRNA transcript and therefore 
allow for the translation of all eight exons (Humphrey 2012).  Treatment of ASOs 
in the SMA mouse model has shown 100% incorporation of exon 7 and a 
significant increase in SMN expression, but the method of local delivery into the 
brain and spinal cord needs optimization (Tsia 2012). Furthermore, some 
scientists argue that local delivery of drugs may not be able to rescue the SMA 
phenotype (Humphrey 2012, Hoa 2011).  The second treatment approach is to use 
small molecules or drugs that stabilize SMN, such as HDAC, proteasome and 
phosphatase inhibitors.  Although some of these small molecules increased SMN 
expression in animal models, clinical trials in patients were largely unsuccessful 
(Xiao 2011).  Another promising treatment approach based on animal model 
results is to use gene therapy with adenoviruses to deliver SMN protein into the 
brain. A virus-mediated drug AA8 was able to increase lifespan by 880% in SMA 
mice.  One disadvantage of gene therapy is the small chance that the adenovirus 
DNA vector could be integrated into the patients genomic DNA.   Another lab is 
currently investigating an adenovirus that is mutated so it is unable to integrate 
into human genomic DNA (Humphrey 2012).  Since, the current SMN-dependent 
drug therapies have not yielded any beneficial results in SMA patients, and SMN 
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has recently been proposed to affect NMJ formation and axonal RNA transport, 
recent investigations in SMN-independent drug targets have also begun (Tsai 
2012). 
1.9 Gemin2 and SMN as the core components of the SMN complex 
There is much to be discovered about the specific functions of each of the 
components of the SMN complex and how each works together to assemble and 
transport RNPs.  The SMN complex is thought to assemble in a systematic 
process with Gemin2 and SMN being the core components (Battle 2007, Liu 
1997).  Both in vivo and in vitro studies suggest a strong and consistent 
interaction between SMN and Gemin2 relative to the other SMN complex 
proteins.   In vitro, Gemin2 has been shown to promote the N terminal self-
association and oligomerization of SMN, while SMN has also been reported to 
stabilize the Gemin2 protein (Owaga 2007, Sarachan 2012) (Figure 1.6).  
Furthermore, the in vitro association of SMN and Gemin2 is extremely stable as it 
is resistant to 1 M NaCl (Lui 1997).  In vivo sedimentation experiments of SMN 
purified from Hela extracts showed that Gemin2 and SMN are the major 
components present in stable complexes larger then 300kDa (Helmken 2000, Liu 
1997,).  In addition, in vivo, SMN localizes with Gemin2 in both the nucleus and 
cytoplasm and the stoichiometry of the two proteins has been shown to be 
important for the formation of neurite RNP granules in motor neurons (Zhang 
2006).  Because the SMN-Gemin2 interaction has been demonstrated to be crucial 
for the function of SMN in motor neurons, understanding the SMN-Gemin2 
interaction is important for uncovering the molecular mechanism of SMN.   
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Figure 1.6- The association of SMN and Gemin2 
Gemin2 self-association and interaction with the N-terminus of SMN (bold 
arrows) increases the stability of the SMN N-terminal self-association (light 
arrow). Figure adapted from Owaga et al 2007. 
 
1.10 Project overview 
 The aim of this project is to characterize the interaction of the SMN 
Gemin2 complex and determine differences between SMN WT and SMN D7 with 
the hope of gaining insights into the molecular mechanism of SMN in the 
pathology of SMA.  Chapter 2 describes the expression and purification of a 
stable N-terminal deletion Gemin2 protein (N45-G2).  N45-G2 was purified via 
nickel affinity chromatography and identified to be more stable and soluble then 
the full-length His-Gemin2 protein.  Initial crystallization resulted in 2µm 
crystals.  Chapter 3 describes the optimization of the expression and purification 
of the SMN WT and SMN D7 proteins.  It was determined that the SMN WT 
expression system was leaky and the toxicity of a small amount of soluble SMN 
protein resulted in a 10-fold decrease of protein expression.   The purification and 
refolding of the SMN protein was optimized, increasing the percentage of 
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refolded protein, protein purity and protein stability. In chapter 3, size exclusion 
chromatography, SDS and Native PAGE identified a one-to-one ratio of SMN-G2 
binding as well as the oligomeric states of SMN, SMN D7 and N45-G2.  
Surprisingly, the heterodimer formation of SMN WT-G2 in vitro was similar to 
that of SMN D7-Gemin2.  However, SMN WT-G2 in vitro favored the formation 
of high molecular weight oligomers, which was less favorable for the SMN D7-
Gemin2 complex. 
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Chapter 2 
EXPRESSION AND PURIFICATION OF GEMIN2 
2.1 INTRODUCTION  
Recombinant expression of proteins in E. coli is the most common 
technique used to obtain the high concentration of purified protein needed for 
protein crystallography and other in vitro protein characterization techniques.  
The success of expressing and purifying recombinant proteins is largely 
dependent on the expression level of the target protein.  The expression level is 
intrinsic to both the vector DNA sequences and the translated amino acid 
sequence of the target protein.  Because of the complexity of the biological dogma 
that takes DNA to RNA followed by RNA to protein, the correlation between the 
DNA sequence of the plasmid transformed into E. coli and the associated protein 
expression level is not well understood.  Several factors are known to have a 
major influence on protein expression such as the toxicity level of the protein, 
RNA hairpin sequences at the 5’ and 3’ UTR of the protein coding sequence, the 
stability and folding of the target protein, and rare codons in the protein mRNA 
sequence (Jana 2005).  In order to overcome some of these issues, induction 
temperature and time are often varied as a way to decrease the rate of 
transcription and translation as well as employing the use of a variety of E. coli 
cell lines that have been genetically altered to address the above factors that 
negatively influence protein expression levels.  These bacterial cell lines aid in the 
decrease of protein toxicity, protease activity and leaky expression and increase 
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the amount of rare tRNAs as well as the folding and stability of proteins 
(Samuelson 2011).   
The aim of this project is to characterize and crystallize the Gemin2 
protein with SMN WT and SMN D7 to understand the role of the SMN complex 
in SMA.  Gemin2 was first discovered as an SMN interacting protein 1 (SIP1), 
with an unknown function and limited homology to the yeast protein Brr1 
involved in snRNP biogenesis (Lui 1997).   Gemin2 has been produced 
recombinantly in E. coli and purified in small-scale microgram amounts most 
often with a GST tag (Ogawa 2007, Friesen 2001).  To characterize Gemin2 in 
complex with SMN, we set out to purify large-scale milligram amounts of 
Gemin2.  While several studies of Gemin2 and SMN have been conducted in 
mammalian cells, very little information is known about the detailed Gemin2 and 
SMN interaction and/or the role that Gemin2 plays in the SMN complex (Fischer 
1997, Jablonka 2001).  We expressed and purified several Gemin2 proteins using 
nickel affinity chromatography. We identified a more stable N-terminal deletion 
Gemin2 protein that resulted in microcrystals.  
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2.2 METHODS 
2.2.1 Cloning 
Full-length gemin2 was PCR amplified from Hela S3 cDNA with forward and 
reverse primers containing a 5’ NdeI and a 3’ XhoI site.  PCR products were 
digested and ligated into pET 28a and pET 30a vectors to create an N-terminal 
histidine tagged gemin2 and native gemin2 construct.  Both native and N-terminal 
histidine tagged Gemin2 clones were verified by sequencing at the ASU DNA lab 
and referred to as His-Gemin2 and Native Gemin2.  Gemin2 constructs encoding 
N-terminal deletions of 14 and 45 amino acids were PCR amplified and ligated 
into the pET 28a vector as above using the same reverse primer and sequence 
specific forward primers.    
2.2.2 Expression 
Gemin2 constructs were transformed into Rosetta PlysS E. coli and single 
colonies were inoculated into 15mL LB cultures with 0.5ug/ul of kanamycin and 
0.35ug/ul of chloramphenicol for 12-16hrs at 30°C overnight.  Overnight 15ml 
cultures were inoculated into 1.5L LB large cultures containing the same 
concentration of antibiotics and grown at 30°C until the OD600 of the bacterial 
culture reached approximately 0.8.  Cultures were brought to 18° or 25°C by 
incubation on ice and induced for 12hrs with the addition of 1mM IPTG.  The 
1.5L cultures were spun down at 6000rpm for 10 minutes and cell pellets were 
frozen at -20°C for future purification. 
2.2.3 Purification 
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Cells were re-suspended in binding buffer (50mM Sodium Phosphate pH 7.4, 
500mM NaCl, 10% Glycerol, 5mM BME) with the addition of DNAse and MgCl2 
at a final concentration of 20mM and sonicated at amplitude of 6 for 1 min 
repeated five times to break open the cells.  Sonicated E. coli lysate was clarified 
via centrifugation at 13,000rpm for 30mins at 4°C and the supernatant was 
incubated with equilibrated nickel beads (GE fast flow 6) at 4°C on an orbital 
shaker.  The bead-lysate mixture was then allowed to settle in a column by gravity 
(biorad) and the lysate was allowed to flow through.  The column was then 
washed with wash buffer containing either 40 or 80mM imidazole and eluted with 
binding buffer containing 250mM imidazole. Fractions were monitored by UV 
absorbance at 280nm and pooled. Purified protein was either dialyzed into a 
HEPES low salt buffer (20mM HEPES pH 7.5, 200mM NaCl, 5% Glycerol, 5mM 
BME), Tris Buffer (20mM Tris HCl pH 8.0, 250mM NaCl, 5-20mM BME) or left 
in elution buffer and stored at 4°C with or with out addition of PMSF or a 
protease inhibitor cocktail (Sigma) , or flash frozen and stored at -80°C.  
2.2.4 SDS PAGE and western blot analysis 
Purified proteins were analyzed by running samples heated at 90°C or incubated 
at 4°C in laemmli buffer with or without BME on a 12% SDS PAGE gel and 
subsequent staining with coomassie dye. Protein samples were either heated at 
90°C for 10 minutes or incubated at 4°C in laemmli buffer with or without BME..  
For Western Blot analysis, samples were run 12% SDS PAGE gel and then 
transferred on ice to a PVDF membrane for 35 minutes at 90V in transfer buffer 
on ice (Tris Glycine Running Buffer containing 0.01% SDS and 20% Methanol).  
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Blots were blocked in PBST with 5% BSA or nonfat milk at 4°C for overnight, 
washed with PBST and then probed with primary (1:3000 anti-His, GE;1:250 
anti-His, Santa Cruz sc-8036 or 1:10,000 anti-SMN –MAMSMA 1, Lorson 1998) 
and secondary (1:10,000 goat anti-mouse HRP, Peirce) antibodies for one hour at 
room temperature in PBST with 5% nonfat milk.  Proteins were detected using 
ECL (Super signal West Pico Chemiluminescent Substrate KIT, Peirce), 
visualized via a CCD imager for 30 seconds to 2 minutes and quantitated using 
Image J software (NIH).     
2.2.5 Crystallization 
Purified His-Gemin2 and His-N45-Gemin2 were either left in imidazole elution 
buffer or buffer exchanged into 20mM Tris HCl pH 8.0, 250mM NaCl with or 
with out 10% glycerol and 5mM BME and concentrated to 1-4mg/ml in a 10kDa 
or 30kDa MWCO Amicon centrifugal units at 4°C. Protein was added to hanging 
drop diffusion crystal trays using the Hampton screen HR2-110 and 112 kits at 
16°C and room temperature.   
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2.3 RESULTS AND DISCUSSION 
2.3.1 Cloning of Gemin2 constructs 
Four gemin2 constructs were created by cloning native gemin2 or N-
terminal deletions of gemin2 into pET30 and pET28 vectors (Novagen).  The 
constructs were designed to express and purify recombinant Gemin2 protein in 
order to characterize Gemin2 and the SMN-Gemin2 complex.  A native gemin2 
construct and a histidine tagged gemin2 construct were created along with two 
additional N-terminal deletion gemin2 constructs, which will be discussed in 
more detail in Section 2.3.6.  Gemin2 cDNA was PCR amplified using the 
appropriate forward (For) and reverse primers (Rev) (Figure 2.1a-c).  The G2 For 
and Rev primers annealed to the 5’ and 3’ ends of the gemin2 cDNA respectively 
to produce full-length gemin2 PCR products.  For the gemin2 deletion PCR 
products, the same G2 Rev primer was used in combination with sequence 
specific forward primers.  The G2-N14 For primer annealed to the gemin2 cDNA 
sequence starting at the DNA sequence that encodes the fifteenth amino acid 
valine and the G2-N45 For primer annealed to the gemin2 cDNA sequence that 
encodes the fourty-sixth proline (Figure 2.1b).  PCR products were digested with 
NdeI and XhoI restriction enzymes and ligated into either the pET28a or pET30a 
vectors (Figure 2.2a-d).  The pET28a vector has an N-terminal histidine tag 
whereas the pET30a vector does not.  Colonies  grown in cultures and purified 
plasmids from each colony were screened by restriction digest to determine if the 
gemin2 insert was ligated into the pET vectors.  Positive clones were verified by 
sequencing at the ASU DNA lab.  We successfully produced four gemin2 
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constructs, two full-length and two with N-terminal deletions that were then used 
to express recombinant Gemin2 protein (Figure 2.2a-d).  Of note, is that both the 
gemin2 deletion primers had mismatched nucleotides between the primer 
sequence and the gemin2 cDNA sequence as shown by the nucleotides that are 
not underlined (Figure 1.2a).  The final sequences did not show any mutations 
from these mismatches, however, these primers would not be ideal for future 
cloning of gemin2.    
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Figure 2.1- Cloning of gemin2 constructs   
Gemin2 cDNA was PCR amplified with the appropriate primers containing a 5’ 
NdeI and 3’ XhoI site shown in Italics.  PCR products were then digested and 
cloned into the designated digested pET vectors to create the four Gemin2 
contructs. (a) Four primer sequences with NdeI and XhoI restriction sites are 
indicated by CAPS and the underlined bold sequence indicates the portion of the 
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primer that annealed to the gemin2 cDNA for PCR amplification. (b) The gemin2 
cDNA sequence with the encoded amino acid sequence above.  Primer annealing 
sites are indicated with bold underlined text.  (c) The forward and reverse primers 
used for each PCR reaction are listed with the corresponding vector each PCR 
product was cloned into and the resulting final DNA construct.   
 
 
 
 
Figure 2.2- Vector maps of gemin2 constructs  
The gemin2 gene was cloned into the various pET vectors with NdeI and XhoI 
restriction sites (italics) to create the DNA plasmid constructs.  The pET vectors 
contained a kanamaycin resistance gene (blue), the lac I gene (green), and a 
Histidine tag (a,c,d). (a) Histidine tagged gemin2 (b) Native gemin2 (c) Histidine 
tagged gemin2 encoding a N terminal 14 amino acid deletion and (d) Histadine 
tagged gemin2 encoding a N-terminal 45 amino acid deletion. 
 
2.3.2 Expression optimization of His-Gemin2 
The verified His-Gemin2 clone (Figure 2.2a) was transformed into Rosetta 
PlysS cells because the amino acid sequence contains both a high percentage of 
rare codons as well as several successive groups of rare codons that are known to 
inhibit the soluble expression of recombinant proteins in E. coli (Kane, 1995).  
His-Gemin2 in Rosetta cells was grown at 37°C and then induced with IPTG for 
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various lengths of time and at various temperatures to determine the optimal 
expression conditions.  After several unsuccessful expression conditions yielding 
less then five milligrams of soluble protein, optimal expression of His-Gemin2 
was achieved by reducing the induction temperature to 18°C for 12 hrs (Figure 
2.3a).  These conditions were determined by a recently published paper 
(Takizawa 2010) and produced a 10 -fold increase of expression compared to 
other similar low temperature expression conditions (Figure 2.3a).  The major 
difference between the previously attempted low temperature induction at 16°C 
for 16hrs  and the successful high expression conditions is that the bacteria culture 
was grown at 30°C instead of 37°C during all growth conditions prior to induction 
(Figure 2.3b).  The difference in growth temperature is likely attributed to the 
additional rare codon tRNAs in Rosetta PlysS E. coli strain.  This is supported by 
the fact that several publications using Rosetta PlysS use similar growth 
temperatures prior to induction and is indicative that lower temperature growth 
prior to induction promotes optimal conditions for the expression, stability and/or 
function of the rare tRNAs encoded by the PlysS plasmid.   
2.3.3 Purification of His-Gemin2 using nickel affinity chromatography  
Over-expressed His-Gemin2 induced at 18°C was run on a nickel affinity 
column to purify it from the remaining E. coli lysate proteins.  Samples were 
collected during each purification step and analyzed via SDS PAGE to determine 
if the purification was successful.  The large 34kDa protein band in the elution 
sample but not in the flow through and wash samples showed that His-Gemin2 
was efficiently purified during chromatography (Figure 2.3b).  The other protein 
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band seen at 75kDa was likely an impurity that bound to the column.  This was 
further confirmed by the observation that increasing the imidazole concentration 
in the wash buffer from 50mM to 75mM led to a significant decrease of the 
75kDa band in the eluted protein fractions (data not shown).   
To verify that the 34kDa protein observed in SDS PAGE was in fact His-
Gemin2, samples were blotted and detected via an anti-histidine antibody with 
His-GFP as a positive control.  The blot indicates that the major purification 
product at 34kDa is in fact His-Gemin2 (Figure 2.3c).  In addition, the blot 
confirms the optimal induction temperature for His-Gemin2 at 18°C.    
 His-Gemin2 was found to be optimally expressed by growing Rosetta 
bacteria cells at 30°C and inducing for 12hrs at 18°C.  In addition, the 34kDa His-
Gemin2 was successfully purified to greater then 80% purity via nickel affinity 
chromatography.   
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Figure 2.3- Expression and purification of His-Gemin2   
(a) His-Gemin2 was induced from 16-25°C for 4-18hrs, E. coli samples were 
lysed and the Gemin2 expression level was determined by analyzing the soluble 
E. coli lysate on an SDS PAGE followed by a western blot using an anti-his tag 
antibody. Expression levels of soluble His-Gemin2 in (mg/1.5L culture) are 
shown relative to a control His-GFP protein in each blot. (b) Large-scale 
expression of E. coli containing the His-Gemin2 construct expressed either at 
18°C for 12hrs or 25°C for 4hs (left portion of the gel).  The plusses indicate 
whole cell induced and uninduced samples as well as soluble and insoluble lysate 
samples. The 18°C soluble E. coli lysate was purified via nickel affinity 
chromatography (right portion of gel). The nickel purification samples include 
flowthrough, wash 1 of binding buffer, wash 2 of 50mM imidazole and elution 
fractions 3-9.  The arrow shows the band corresponding to His-Gemin2.  (c) The 
expression and purification samples in (b) were analyzed by western blot anlaysis 
using an anti-his tag antibody. His-GFP was used as a positive control. 
   
2.3.4 Solubility of His-Gemin2 protein 
His-Gemin2 in elution buffer precipitated out of solution at 4°C.  In order 
to increase the solubility of purified His-Gemin2 for future characterization, His-
Gemin2 was immediately dialyzed after purification into several buffers 
containing a range of concentrations of salt and beta-mercapetoethanol (BME).   
Upon dialysis into HEPES buffer including a high concentration of BME, a 
solubility limit of 1.0 OD280 was obtained (Table 2.1).  Previous studies have 
shown that the majority of recombinant Gemin2 is in the dimer form with a small 
portion in the trimer and monomer forms (Ogawa 2007).  The higher BME 
concentration may have increased the solubility of the protein by reducing 
disulfide bonds and decreasing aggregation.            
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Buffer  OD280 
Elution buffer  
(500mM NaCl, 250mM imidizole) 
NA (all crashes out) 
20mM Tris pH 8.0 0.50 
20mM HEPES pH 7.5 0.40 
20mM HEPES  
(no salt, no glycerol) 
NA (all crashes out) 
20mM HEPES pH 7.5  
(20mM BME) 
1.00 
 
Table 2.1- Solubility limit of His-Gemin2 
His-Gemin2 protein was dialyzed into buffers containing 10% Glycerol, 200mM 
NaCl and 5mM BME or left in elution buffer at 4°C overnight. Changes to buffer 
conditions are indicated in parentheses.  After dialysis, the protein was 
centrifuged and the remaining amount of soluble protein was determined by 
measuring the absorbance at 280nm.   
 
2.3.5 The degradation of His-Gemin2 
Although the HEPES buffer increased the solubility of His-Gemin2, after 
several days at 4°C His-Gemin2 continued to crash out of solution and appeared 
to undergo degradation.  In an effort to inhibit the degradation of His-Gemin2, the 
protease inhibitor PMSF was added to His-Gemin2 and samples of His-Gemin2 
with and without protease inhibitor were monitored for degradation over several 
days at 4°C.  Even in the presence of PMSF, His-Gemin2 was degraded into 
several smaller molecular weight bands, which started at day three of incubation.  
In addition, His-Gemin2 continued to precipitate out of solution over time (Figure 
2.4a).  
The same stability test was repeated with a commercial protease inhibitor 
cocktail.  The degradation of His-gemin2 occurred in the presence of PMSF as 
well as a protease inhibitor cocktail (2.4b). The two main degradation fragments 
at approximately 32kDa and 30kDa were calculated to have a loss of 1.50kDa and 
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5.01kDa respectively excluding the histidine tag and linker sequence.  A western 
blot of degraded His-Gemin2 was run to give insight into the location of the 
protein cleavage. The anti-histidine antibody only detected the full-length His-
Gemin2 protein suggesting that the degraded His-Gemin2 fragments contained at 
least an N-terminal deletion (Figures 2.4 b-c).  It may be possible that the His-
Gemin2 fragments were not detected due to both a lower concentration and/or 
because of inefficient transfer due to their lower molecular weights, however, the 
detection of the 29kDa His-GFP protein makes the later unlikely.   
His-Gemin2 was purified to twenty milligram per liter amounts, but 
precipitated out of solution and degraded after several days even in the presence 
of protease inhibitors.  Due to the lack of solubility and stability, we concluded 
that His-Gemin2 was not an ideal protein for crystallography studies and further 
biochemical analysis.    
 
 
 
  32 
 
 
Figure 2.4- Stability of His-Gemin2 
(a) His-Gemin2 in HEPES buffer with or without PMSF was incubated at 4°C for 
7 days and aliquots were spun down and the soluble protein for each aliquot along 
with the precipitated protein (ppt) was analyzed by SDS PAGE for degradation. 
(b) His-Gemin2 was incubated at 4°C for 5 days in HEPES buffer only or with the 
addition of PMSF and a protease inhibitor cocktail from Sigma and analyzed for 
degradation by SDS PAGE.  (c)  Degraded His-Gemin2 in HEPES buffer from (b) 
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was probed via an anti-his tag antibody along with the control His-GFP.  The 
arrow indicates the full-length His-Gemin2.   
 
2.3.6 Predicted His-Gemin2 cleavage sites and the design of cleavage-resistant 
Gemin2 constructs 
A secondary structure analysis of the N and C termini of His-Gemin2 was 
conducted to aid in the prediction of His-Gemin2 cleavage sites.  The analysis 
predicted three alpha helices and a beta sheet at the N-terminus and four longer 
alpha helices at the C-terminus (Figure 2.5a).  The location of the cleavage sites 
were estimated by using the calculated molecular weight of the two main 
degradation fragments observed in Section 2.3.5 and subtracting that molecular 
weight from full-length Gemin2.  The estimated molecular weight loss of 
1.05kDa and 5.01kDa for the two major degradation fragments was then mapped 
onto the secondary structure of Gemin2 at the N and C termini as the possible 
cleavage sites.  A sequence analysis to identify a protease that was specific for 
each of the four possible cleavage sites did not yield any significant results.  The 
N-terminal cleavage sites were predicted to be the actual cleavage or degradation 
sites because they are located in regions lacking defined alpha helical and beta 
sheet secondary structures while the C-terminal predicted cleavage sites are 
located in the middle and at the end of an alpha helix (2.5a). Furthermore, the 
confidence level of the first two N-terminal alpha helices is low relative to the 
alpha helices at the C-terminus suggesting that the probability of those alpha 
helices forming in the actual structure is less likely.  An in vivo study showed that 
deletion of the first 45 amino acids of Gemin2 had no affect on the interaction of 
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SMN and Gemin2 (Ogawa 2007).  The N-terminal cleavage sites located within 
predicted random coiled secondary structure, the lack of detection of the N-
terminal histidine tag and the lack of SMN binding in vivo provide evidence that 
the N-terminus of His-Gemin2 was degraded in vitro.   However, the possibility 
that His-Gemin2 was cleaved at both the N and C termini cannot be ruled out.   
In order to create a more stable and soluble Gemin2, two new N terminal 
deletion proteins were cloned in which 14 and 45 amino acids corresponding to 
the two predicted cleavage sites were deleted from the N-terminus (Figure 2.5b).  
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Figure 2.5- Predicted cleavage sites and Gemin2 deletion constructs 
(a) The Gemin2 N and C terminal sequences were analyzed via a secondary 
structure prediction software (Expasy molecular weight tool. Alpha helices (pink) 
and beta sheets (yellow) predicted with a confidence level (blue) by PSIPRED 
protein structure prediction server.  The lines show the predicted cleavage sites on 
the Gemin2 sequence that correlate to the two main cleavage fragments (loss of 
1.50 and 5.01kDa) seen in SDS PAGE. (b) The 14 and 45 amino acid N-terminal 
deletion constructs were designed and cloned to create His-N14-Gemin2 and His-
N45-Gemin2. The N-terminal sequence of full-length His-G2 is shown below the 
sequences of the two deletion constructs with the histidine tag red. 
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2.3.7 Gemin2 deletion construct expression and purification  
The two deletion proteins, His-N14-Gemin2 and His-N45-Gemin2, were 
expressed and purified as was previously done with His-Gemin2 in sections 2.3.2-
3 and will be referred to as N14-Gemin2 and N45-Gemin2.  Elution fractions 
from nickel affinity purification showed bands that migrated at the expected size 
of N14-Gemin2 and N45-Gemin2 of approximately 32kDa and 30kDa 
respectively, which also migrated the same distance as the two degraded 
fragments shown previously (Figure 2.6a).  The lack of an over-expression band 
in the soluble lysate along with the lower amount of purified protein showed that 
the expression of the Gemin2 deletion proteins is significantly less then the full-
length His-Gemin2 with the N45-Gemin2 protein expressing at a higher level then 
N14-Gemin2. 
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Figure 2.6- Expression and stability of N45-Gemin2  
(a) Deletion Gemin2 proteins were expressed and purified similarly to His-
Gemin2. Proteins were dialyzed into HEPES buffer after purification and 
analyzed by SDS PAGE.  (b) The stability of protein in HEPES and elution buffer 
was analyzed at 1 and 5 days after incubation at 4 and 25°C. (c) The stability of 
the two proteins was analyzed after 5 and 13 days in HEPES buffer.  Asterisks 
indicate the expected molecular weight of the N14-Gemin2 protein and arrows 
indicate the N45-Gemin2 protein 
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2.3.8 Comparison of N14-Gemin2 and N45-Gemin2 protein stability 
In order to test the stability of these two constructs, each protein was 
incubated in HEPES or elution buffer at 4 or 25°C for five days and degradation 
and precipitation were analyzed by centrifugation followed by SDS PAGE.  After 
five days, each of the proteins in HEPES buffer did not precipitate out of solution 
while N14-Gemin2 underwent slight degradation, as the 25kDa band appears to 
be more intense (Figure 2.6b).  Both proteins were degraded at 25°C in HEPES 
buffer, but N45-Gemin2 in elution buffer was unexpectedly still present at 25°C.  
Unlike full-length His-Gemin2, the deletion Gemin2 proteins were more stable in 
elution buffer then HEPES buffer and the stability at room temperature points to 
an overall increase in protein stability.   
Proteins were incubated at 4°C for over two weeks to determine if the 
proteins would be stable enough for crystallography trials.  After 13 days in 
HEPES buffer, both proteins were still present, but N45-Gemin2 appeared slightly 
more stable then N14-Gemin2 as indicated by a larger degradation smear at 
25kDa in the N14-Gemin2 sample (Figure 2.6c).   
N45-Gemin2 and N14-Gemin2 were successfully expressed and purified.  
The deletion Gemin2 proteins had lower expression and purification yield relative 
to His-Gemin2, but the deletion proteins were more stable and soluble.  N45-
Gemin2 was used for further crystallizing and biochemical characterization 
experiments because of its higher stability and expression level.    
2.3.9 Optimization of N45-Gemin2 stability 
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N45-Gemin2 was buffer exchanged and concentrated in HEPES and 
elution buffers to determine the optimal buffer conditions for future experiments.  
As was predicted from the previous section, N45-Gemin2 is more stable in elution 
buffer as all the protein in the HEPES buffer was degraded (Figure 2.7a).  Either, 
the increased amount of salt, the buffer composition or possibly the presence of 
imidazole may stabilize N45-Gemin2.  N45-Gemin2 in high salt buffer may favor 
stable monomers or oligomers instead of aggregation.  It has been shown that 
imidazole stabilizes histidine tag proteins and sometimes facilitates 
crystallization, so it may be possible that imidazole aids in the solubility and/or 
stabilization of N45-Gemin2 (Hamilton 2003).  It was concluded that elution 
buffer resulted in a more stable N45-Gemin2 protein. 
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Figure 2.7- Stability of N45-Gemin2 
(a) N45-Gemin2 was incubated in elution buffer or HEPES buffer at 4°C for 
several days and analyzed for stability.  (b) Two N45-Gemin2 purified protein 
samples from different preps (A and B) were concentrated to 1.5 and 3.0 OD280 
respectively and analyzed for stability.  Each prep was purified using the same 
conditions except that prep B was purified with an optimized imidazole wash 
buffer of 80mM imidazole whereas prep A used 50mM imidazole.  (c).  Western 
blot analysis of  prep A, prep B and an elution fraction were transferred to a blot 
and probed with an anti-his tag antibody. (d) Degraded N45-Gemin2 from prep A 
and full-length N45-Gemin2 from prep B were run on SDS PAGE and analyzed 
via western blot (anti-his tag). 
 
Next, N45-Gemin2 was concentrated to ascertain whether the appropriate 
concentration range and purity for crystallography and biochemical analysis could 
be obtained.  N45-Gemin2 from two separate preparations, prep A, prior to nickel 
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affinity optimization and prep B, after the optimization of imidazole 
concentration, was concentrated  and analyzed via OD280 and SDS PAGE.  Prep A 
and B were concentrated to an OD280 of 1.5 and 3.0 respectively (2.4 and 
1.2mg/ml).  Protein in prep A was degraded from a 30kDa band to a major band 
at 25kDa while prep B did not (Figure 2.7 b).  Also of note, is that the more 
concentrated N45-Gemin2 in prep B had several higher molecular weight 
impurities that would not be ideal for crystallization.  The degradation of N45-
Gemin2 in prep A was likely due to the lower purity of the protein sample.  
Another possibility is that the degradation of N45-Gemin2 from prep A, which 
was stored at 4°C for several weeks longer then prep B, resulted from degradation 
during storage.  Interestingly enough, degradation did not occur or occurred at a 
slower rate in dilute N45-Gemin2 samples suggesting that concentration 
promoted degradation possibly due to a high concentration of co-purified 
proteases (data not shown).  N45-Gemin2 was able to be concentrated to 2.4 
mg/ml, which was higher then the 1.6 mg/ml of His-Gemin2, but concentrated 
N45-Gemin2 degraded slowly over a several week time span and still contained 
some impurities. The inefficient concentration and degradation of N45-Gemin2 
was not ideal, but determined to be sufficient for future characterization and/or 
purification steps.     
Before characterization of N45-Gemin2, a western blot using an anti-
histidine antibody was conducted to confirm the presence of the N45-Gemin2 
protein.  Full-length N45-Gemin2 protein was detected at the expected molecular 
weight of 30kDa (Figure 2.7c).  In addition, a small portion of N45-Gemin2 
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migrated as a 60kDa SDS-resistant dimer in the concentrated N45-Gemin2 
sample.  This suggests that the self-association of Gemin2 is relatively strong as a 
percentage of intermolecular disulfide bonds were likely still present under SDS 
PAGE conditions.  The observed dimer detected by western blot analysis as well 
as the fact that Gemin2 was able to be concentrated in a 30kDa molecular weight 
cut off concentrator without protein loss (data not shown) provided evidence that 
N45-Gemin2 retained the ability to self-associate.  Since, Gemin2 self-association 
is important for SMN-self association, we predicted that N45-Gemin2 should be 
able to bind SMN and mimic the native SMN-Gemin2 interactions in vitro.    
Concentrated N45-Gemin2 continued to degrade during incubation at 4°C 
after two weeks.  Degraded and full-length N45-Gemin2 were analyzed via SDS 
PAGE and Western Blot to determine if the degradation occurred at the N or C 
termini.  Full-length and degraded N45-Gemin2 are shown at 30kDa and 25kDa 
respectively on SDS PAGE, but the western blot with an anti-histidine antibody 
only detected the full-length protein at 30kDa (Figure 2.d).  This provides 
evidence for further N-terminal degradation of the N45-G2 protein over time 
and/or upon concentration.  
In conclusion, N45-Gemin2 was more stable and soluble then His-
Gemin2. N45-Gemin2 likely retained the native Gemin2 function of self-
association, which is important for future SMN-Gemin2 interaction studies.  The 
N45-Gemin2 protein underwent the same degradation as full-length Gemin2 at a 
slower rate.  The continual degradation of all three Gemin2 constructs may be 
caused by an unstructured N-terminal region of Gemin2.  The recently published 
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crystal structure of Gemin2 supports this as the first 45 amino acids are highly 
disordered and serve to fill space in the RNA binding pocket of the Sm proteins 
D1, D2, E, F and G  (Zhang 2011).  Furthermore, residues from 45 to 90 in the 
crystal structure are disordered, but are bound to Sm proteins, suggesting that this 
interaction stabilizes Gemin2.  Another recent paper showing the solution 
structure of Gemin2 bound to an alpha helix of SMN protein containing residues 
26-51 reported that even the small alpha helix region of SMN stabilized the 
flexible Gemin2 protein (Sarachan 2012).  Other recombinant Gemin proteins and 
Sm proteins show similar degradation patterns in vitro, Gemin6, Gemin7 and 
several Sm proteins were all purified and/or co-expressed with a binding partner 
(Ma 2005, Zhang 2012).  This suggests that in the absence of a binding partner 
the sm-protein fold of Gemins and Sm proteins may be disordered and thus easily 
degraded.  It is likely that these proteins interact immediately after translation in 
vivo and this interaction could even be part of the regulation of the SMN complex. 
In agreement with the idea that cleavage and degradation is crucial for the 
regulation of the SMN complex, Gemin2 and SMN have both been shown to be 
cleaved by Calpain (Fuentas 2010).   
2.3.10 Crystallization of N45-Gemin2 
In an attempt to determine the molecular structure of N45-Gemin2, 
crystallization trials of purified N45-Gemin2 were conducted.  Concentrated N45-
Gemin2 was screened using the Hampton crystal screen and three conditions 
produced crystals (Table 2.2).  Microcrystals observed in condition 16 are shown 
in Figure 2.8.   
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Crystal Screen- # Well reagents Temperature 
HR2-110 -#16 0.1M HEPES pH 7.5, 1.5M lithium 
sulfate 
16 and 25°C 
HR2-110 -#17 0.2M Lithium sulfate, 0.1M Tris HCl 
pH 8.5, 30% PEG 4000 
16°C 
HR2-112 -#41 0.01M Nickel (II) Chloride hexahydate, 
0.1M Tris HCl pH 8.5, 1.0M Lithium 
sulfate 
16 and 25°C 
 
Table 2.2- Crystallization conditions for N45-Gemin2 
Hampton Screen HR2-110 and 112 was used to screen for optimal crystal 
conditions.  The three conditions listed resulted in 2um crystals, all of which 
contained lithium sulfate as a comment reagent.  
 
 
Figure 2.8- Crystallization of N45-Gemin2 
N45-Gemin2 was crystallized in 0.1M HEPES pH 7.5, 1.5M lithium sulfate using 
the hanging drop method.  Crystals were approximately 2 µm in size.   
 
Crystals of approximately 2 µm were observed using the hanging drop method at 
room temperature in approximately one day (Figure 2.8).  Further attempts to 
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optimize these initial conditions were unsuccessful.   In the process of optimizing 
the conditions to produce larger crystals, the crystal structure for Gemin2 was 
published (Zhang 2011).  Further optimization of Gemin2 crystals was abandoned 
and focus was turned towards investigation of the interaction between SMN and 
Gemin2 proteins. 
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Chapter 3 
EXPRESSION AND PURIFICATION OPTIMIZATION OF SMN 
3.1 INTRODUCTION 
Since the 1990’s when SMN was identified as the protein link to spinal 
muscular atrophy, intense efforts have been made to understand its function in 
motor neurons.  Biochemical techniques such as crystallography and NMR that 
give structural clues about the function of proteins have been unsuccessful with 
full-length recombinant SMN protein.  The structure of the Tudor domain of 
SMN was solved showing the interaction of SMN with Sm-proteins via their 
arganine-glycine tails.  Interestingly, the Tudor domain adopted a partial Sm-fold 
similar to Sm proteins and Gemins 6 and 7 (Selenko 2001).   
Several labs have expressed SMN as a recombinant protein in E. coli with 
a wide variety of fusion tags, but the majority of the protein is insoluble and the 
small amount of soluble protein forms large oligomers (Takaku 2011,Pellizzoni 
1999).  SMN with an N-terminal thioredoxin tag and a C-terminal histidine tag 
(SMN TRX) was refolded from inclusion bodies using dialysis and determined to 
form large oligomers or soluble aggregates greater then 600kDa by size exclusion 
chromatography (SEC) (Young 2000b, Nguyen thi 2008).  Similarly, Zhang et al 
was able to co-express soluble recombinant SMN with the Gemin2 protein, but 
stated that the purified SMN-Gemin2 proteins failed to form protein crystals due 
to the heterogeneity of the proteins observed on SEC (Zhang 2011).  Tukaku et al 
created a fusion protein by linking SMN to Gemin2 with an amino acid sequence 
and was able to produce a soluble SMN-Gemin2 fusion protein (Tukaku 2011).  
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Their results showed that the SMN-Gemin2 fusion protein restored function in 
SMN knockout chicken cells.  However, because the function of chicken SMN 
has been shown to be different then human SMN, these results may not provide 
direct evidence that the fusion SMN-Gemin2 protein would change the structure 
and/or function of the human proteins (Wang 2001).  
The majority of the biochemical insights about the SMN complex were 
determined by experiments in mammalian cells or rabbit raticulocyte lysate 
(RRL).  This suggests that post-translational modifications, chaperone proteins 
and post-translational binding to other proteins stabilize the SMN protein.  In 
agreement with this is the observation that the phosphorylation state of SMN was 
crucial for in vivo localization and binding to other proteins (Petri 2007).   The 
disadvantage of using partially purified proteins from RRL or mammalian cells is 
that the protein of interest is bound to several other proteins, which makes the 
biochemical analysis more complex and indirect.  In addition, these techniques 
are not ideal for expressing the large amounts of pure protein needed for 
crystallographic and other biochemical studies.           
 SMN WT has been previously expressed, purified and crystallized in our 
lab (Seng, unpublished).  The following observations led to the optimization of 
the SMN expression and purification protocol.  First, the cell growth of the E. coli 
containing the SMN WT construct was two-fold slower then the exponential 
growth normally observed in recombinant expressing Bl21 cells.  The growth was 
restored after transformation of the SMN WT plasmid into fresh competent Bl21 
cells. These observations indicate that SMN is toxic to the cells even prior to 
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induction.  Second, over-expression of SMN WT at the predicted size of 38kDa-
40kDa was not observed after induction, but upon the addition of glucose into the 
growth media, a small amount of over-expressed protein at 34kDa was observed 
(Campanaro 2009).  Glucose is known to inhibit leaky expression in E. coli 
strains using the lac operon for induction and the over-expressed protein at 34kDa 
indicates that SMN WT migrates at 34kDa in SDS PAGE.  After purification and 
refolding with nickel affinity chromatography, several low intensity protein bands 
were observed on a SDS PAGE gel, none of which was in the predicted 38-40kDa 
range for SMN WT.  These results suggest a low expression, purification and/or 
stability for purified SMN WT.  
This chapter describes the optimization of the expression and purification 
of SMN WT.  The yield of recombinant SMN protein was increased by 
optimizing the expression, purification and stability with the overall aim of 
characterizing the interaction of recombinant SMN and Gemin2 in vitro.  SMN 
WT was expressed employing various conditions, including varying cell strains, 
induction temperature and time and media additives. Denatured SMN proteins 
were purified and refolded using nickel affinity chromatography and dialysis.  
Lastly, purified SMN proteins were incubated and concentrated in several buffer 
conditions and analyzed via standard and non-reducing SDS PAGE to increase 
the overall stability of SMN protein.    
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3.2 METHODS 
3.2.1 Constructs 
Constructs containing full-length SMN (SMN WT) and SMN lacking exon 7 
(SMN D7) were previously cloned into the pRSETc vector with an N-terminal 
histidine tag (Campanaro 2009).   SMN TRX was obtained from another lab 
(Young 2000b).  SMN TRX was constructed by cloning full-length SMN into the 
pET32 vector, which contains an N-terminal thioredoxin (TRX) tag and a C-
terminal histidine tag.   
3.2.2 Expression optimization 
SMN and SMN D7 constructs were transformed into BL21 and Rosetta PlysS 
cells.  Single colonies were inoculated into 3mL of SOB media with or without 
0.5% glucose, 1.0ug/ul of ampicillin, and 0.35ug/uL of chloramphenicol (Rosetta 
PlysS).  Small cultures were incubated at 30°C or 37°C and shaken at 300rpm for 
12-16hrs. Small cultures were then inoculated 1:100 into either 50mL or 1.5L 
large SOB cultures and grown until the OD600 reached approximately 0.8- 1.0.  
Large cultures were induced with 1mM IPTG at either 18°C, 25°C or 37°C and 
grown for 4-16hrs.  Cells were centrifuged at 6000rpm for 10 minutes and frozen 
at -20°C.       
3.2.3 Inclusion body purification and nickel column refolding 
Bacterial cell pellets were resuspended (5ml/g cell paste) in PBS with a spec of 
DNase powder and a final MgCl2 concentration of 20mM.  The resuspended 
lysate either was sonicated or underwent 3-5 freeze/thaw cycles (Rosetta cells) to 
lyse cells, incubated with 1% Triton X for 5 minutes and spun down at 13,000rpm 
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for 30 minutes. This inclusion body extraction was repeated with addition of 
DNase, MgCl2 and 1% Triton X, and again with 2M Urea both in PBS buffer. 
Purified inclusion bodies were solubilized in 50ml of buffer A (50mM sodium 
phosphate pH 7.5, 500mM NaCl, 8M Urea) with addition of 20mM BME 
overnight at 4°C for 12hrs or at room temperature for 2hrs.  Solubilized inclusion 
bodies were clarified again by centrifugation at 13,000rpm for 30 minutes and the 
supernatant was incubated with nickel beads (Fast flow 6, GE) equilibrated with 
buffer A for one hour at 4°C.  The lysate-bead mixture was then settled by gravity 
in a column (Biorad) and washed with buffer A + (buffer A containing 20-40mM 
imidazole).  The bound protein was then refolded by addition of 10 column 
volumes each of a 6-step gradient transitioning from denaturing buffer A to native 
Buffer B (50mM sodium phosphate pH 7.5, 500mM NaCl, 500mM Sucrose) at 
the following ratios: 50:10ml, 40:20ml, 30:30ml, 20:40ml, 10:50ml, 0:60mL.  The 
folded protein was then eluted with elution buffer (buffer B containing 250mM 
imidazole and lacking 500mM sucrose).  Eluted fractions were monitored via UV 
absorbance at 280nm and pooled for SDS PAGE and Western Blot analysis as 
described in Chapter 2.   
3.2.4 Denaturing Nickel Column Purification and Dialysis Refolding 
The same process above was repeated excluding the six step gradient and protein 
was eluted in buffer A containing 250mM imidazole.  Denatured protein fractions 
were pooled based on the absorbance at 280nm,  dialyzed for 2hrs each against 
2M, 1M, 0.5M, 0.25M Urea in PBS and finally for 8 hrs against PBS at 4°C and 
then frozen at -20°C.  
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3.3 RESULTS AND DISCUSSION 
3.3.1 SMN constructs 
Three plasmid constructs were used to express recombinant SMN WT and 
SMN D7 proteins.  His-SMN WT and His-SMN D7 sequences have been 
previously cloned into the pRSETc vector with a modified shortened linker 
sequence containing a single glycine between the histidine tag and the first 
methionine of the SMN protein (Figure3.1). The SMN WT and D7 sequences are 
similar but vary in sequence at the C terminus due to an exon seven exclusion and 
the consequent early translation termination.  The third construct, SMN TRX was 
obtained because of its high stability and solubility (Nguyen thi 2008).  The 
12kDa thioredoxin tag is often used to increase the solubility of proteins refolded 
from bacterial inclusion bodies (Shahdev 1998).   
 
 
Figure 3.1- SMN constructs 
The amino acid sequences of both SMN WT and SMN D7 are shown with the 
histadine tag (orange) followed by a glycine linker and the start codon of the 
native protein sequences (red).  SMN D7 varies in sequence from WT at the C 
terminal end (orange).  The SMN TRX construct contains an N-terminal 
Thioredoxin tag (green) and a C-terminal histidine tag (orange).   
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3.3.2 SMN expression optimization 
The E. coli containing the SMN WT construct was observed to have a 
two-fold decrease in growth.  SMN WT was expressed in Rosetta and Bl21 cells 
and samples of bacterial cells were analyzed before and after induction.  Cells 
were also lysed and separated by centrifugation to analyze soluble and insoluble 
samples to determine if the leaky expression of SMN WT caused the decline in 
the bacterial growth rate.  SMN WT in BL21 cells showed a large expression 
band in both the un-induced and induced whole cell samples whereas the Rosetta 
cells only showed SMN expression in the induced sample and a weak expression 
band in the un-induced sample (Figure 3.2a).  The leaky expression of SMN WT 
in Bl21 cells was abolished in Rosetta cells by the extra PlysS plasmid that 
encodes for T7 Lysozyme.  The excess T7 Lysozyme functions to degrade extra 
T7 RNA polymerase and prevent nonspecific transcription of the target gene 
controlled by the lac operon. The insoluble Bl21 samples showed high SMN 
expression before and after induction with IPTG, while the soluble fractions 
showed a small amount of SMN expression.   Over-expressed proteins that form 
inclusion bodies are not toxic to the cell making the small amount of soluble 
expressed SMN in the BL21 cells the likely culprit for the observed slow bacterial 
growth in Bl21 cells.  The toxicity of the SMN protein along with the known 
plasmid instability of the pRSETc vector likely resulted in low expression levels 
of SMN WT (Dumon 2004, Walia 2008).  Since, the SMN protein and plasmid 
are toxic and unstable to the bacterial cells; the cells in the glycerol stock during 
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growth could have recombined the unstable DNA plasmid, failed to propagate the 
plasmid during cell division or died due to protein toxicity.   This also explains 
the restoration of SMN expression and normal cell growth after re-transformation 
of SMN WT plasmid into fresh Bl21 competent cells.   
To prove that Rosetta cells increase the long-term stability of SMN 
expression, SMN WT was expressed from both a Bl21 and Rosetta glycerol stock 
and the expression was measured by detecting SMN via a western blot.  Bl21 
cells grown from a glycerol stock showed a low amount of SMN WT expression 
at 2mg per 1.5L whereas SMN WT expressed in Rosetta cells showed a 5-fold 
increase at 18°C (Figure 3.2b).  Rosetta cells also permanently rescued bacterial 
growth and have the capacity to increase SMN WT expression to approximately 
10-fold to 20mg/1.5L at 37°C.  The 37°C growth condition was not chosen due to 
high amounts of partially translated SMN protein (data not shown). The Rosetta 
cells increased the expression  of SMN WT, stabilized the expression system and 
also verified that SMN WT migrates at approximately 34kDa in our conditions 
instead of the predicted 38-40kDa.   
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Figure. 3.2. Optimization of SMN expression 
(a) SMN was grown in BL21 (DE3) and Rosetta PLysS cells and induced for 
3hrs.  Whole, soluble and insoluble cell fractions were collected before and after 
induction and analyzed via SDS PAGE and western blot analysis using an anti-
SMN primary antibody. SMN WT protein is labeled just below 40kDa. (b) the 
SMN WT construct in Bl21 and Rosetta cells was inoculated from a glycerol 
stock and expressed for 12hrs.  Relative expression was estimated by 
quantification of western blot analysis using purified His-GFP as a control. 
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3.3.3 Comparison of dialysis and nickel column refolding 
SMN TRX a construct received from Dr. Glenn Morris was shown to have a high 
purification yield using dialysis refolding to refold SMN from inclusion bodies 
(Young 2000b).  A comparison between nickel column refolding and dialysis 
refolding was made to determine the most efficient technique.  SMN WT and 
TRX proteins were both dialyzed and refolded on a nickel column and analyzed 
via absorbance at 280nm and SDS PAGE.  The purification resulted in similarly 
pure protein in both dialysis and nickel column refolding (data not shown).  The 
overall yield of each SMN protein was similar for both refolding techniques 
(Table 3.1).   However, the concentration of the dialyzed refolded protein was 
significantly lower for SMN WT.  This was likely due to SMN WT aggregates 
diffusing through the dialysis bag and nucleating aggregation of other partially 
folded or native SMN proteins.  Furthermore, on-column refolding took an 
additional hour of purification after nickel affinity chromatography whereas 
dialysis took an additional 16hrs.  SMN TRX had a higher yield using the dialysis 
method, but was less stable then SMN WT (shown below).  In sum, these results 
show that nickel column chromatography is the most efficient method of 
refolding SMN from inclusion bodies.    
 
 Dialysis  
(A280/ml) 
Nickel Column  
(A280/ml) 
Total Protein 
Yield (A280) 
SMN WT 0.08-0.20 (ppt) 0.10-0.30 ~ 2.0-4.6 
SMN TRX 0.80 0.29 ~ 3.0-8.0 
Table 3.1- Comparison of refolding techniques 
SMN WT and TRX were purified and eluted under denaturing conditions and 
dialyzed in a 4 step gradient with decreasing  urea and increasing PBS or purified 
and refolded on-column.  Purified protein was detected by measuring the 
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absorbance at 280nm.  Ppt indicates precipitation of protein was observed during 
refolding.   
 
3.3.4 Increased refolding efficiency and purity of SMN WT 
After expression of SMN WT was increased by approximately five-fold, 
the concentration and total yield of eluted protein did not increase as expected, but 
instead decreased dramatically. Since, the increase in SMN expression was the 
only variable changed in the purification process, it was hypothesized that the 
higher bead binding capacity of the Nickel beads (40mg/ml) induced aggregation 
during protein refolding on the column.  To verify that the higher expression level 
of SMN WT caused aggregation during refolding, SMN WT was purified using 
the recommended conditions of 1ml of nickel beads with a 40mg/ml binding 
capacity as well as 5ml of older nickel beads with a lower bead binding capacity.  
The elution fraction of the 1ml bead purification contained barely detectable 
amounts of SMN WT compared to the SMN WT eluted from the 5ml bead elution 
showing that SMN aggregation during folding caused the decreased yield in SMN 
(Figure 3.3a).  Aggregated SMN WT was not eluted with high imidazole buffer.   
This was most likely because of a strong hydrophobic interaction between the 
nickel resin and aggregated protein seen in previous studies and was further 
confirmed by a significant decrease in column flow rate during refolding 
(Sweitnicki 2006).  In addition, increasing the bead volume to 10ml further 
increased the overall yield of SMN WT.  The elution fraction of the SMN WT 
purification contained an impurity just above 40kDa (Figure 3.3a).  To optimize 
the purification, SMN WT was purified and eluted under denaturing conditions 
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with a step gradient of imidazole.  SMN WT eluted in the 150mM imidazole 
fraction while the 40kDa impurity eluted at 38mM imidazole, which showed that 
an increase in imidazole to 40mM could remove the purity (Figure 3.3 b).     
The increase in nickel beads led to an increase in overall yield from 
approximately 2mg to 4.6 mg per nickel purification. The increase in yield was 
coupled with an increase in efficiency because instead of using one cell pellet for 
the purification, only one third of the sonicated and urea-solubilized pellet was 
used to ensure that SMN WT did not saturate the beads during binding.  In 
addition, the impurity at 40kDa comprised about 50% of the total purified protein 
and without it the purity of SMN WT increased to greater then 95%.           
 
 
Figure 3.3- Optimization of nickel affinity SMN purification 
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(a) SMN WT was purified via nickel affinity chromatography under denaturing 
conditions, refolded on-column with a decreasing urea gradient and then eluted 
with high imidazole buffer.  The top panel shows SMN WT purified using 1ml of 
nickel beads with a high binding capacity of 40mg/ml. E. coli lysate and elution 
fractions from two purifications are indicated (3 and 7 gram pellet). The lower 
panel shows purification with 5mls of lower binding capacity beads. E. coli lysate 
and elution fractions are indicated as well as flow through, buffer A (Binding 
buffer), and buffer A+ (Binding buffer containing 20mM imidazole).  SMN WT 
is indicated with an arrow and an impurity with an asterisk (b) Urea-denatured 
SMN WT lysate was bound to 5mls of low capacity binding nickel beads, washed 
and eluted with a step gradient of imidazole in urea denaturing buffer.  SMN WT 
is indicated with an arrow.  
 
3.3.5 SMN WT and D7 purification  
SMN WT and D7 were purified by nickel chromatography and the purified 
proteins were assessed for stability one day later.  SMN WT and D7 in the eluted 
fractions migrated as a smear at 34kDa (Figure 3.4a).   Both SMN proteins 
underwent degradation.  In addition, both proteins migrated as a 100kDa 
SDS=resistant trimer band.  This band is unlikely to be an impurity because it was 
not present in SMN purified and eluted under urea denaturing conditions.  The 
observed oligomers at 100kDa in SDS PAGE are in agreement with the low-
resolution structure of SMN WT, which showed two trimers forming a pseudo 
hexamer (Seng, unpublished).  Wan et al showed that native SMN in rabbit 
raticulosyte (RRL) was able to form SDS-resistant dimers and a small amount of 
trimers via two conserved cysteine residues in the N and C termini (Wan 2008). 
The trimers may not have been a major product in their study because RRL 
contains chaperones and other SMN complex proteins that when bound to SMN 
could have sterically hindered trimer formation and/or the necessary disulfide 
bonds.  However, we cannot rule out the fact that the degradation of our SMN 
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WT in SDS conditions caused the disulfide linked SDS-resistant trimer.  Another 
interesting difference between our results and the Wan et al results was that SMN 
D7 did not form SDS-resistant dimers and trimers whereas our recombinant SMN 
D7 does form trimers.  Again, this points to the idea that SMN WT and SMN D7 
have similar abilities for disulfide bond formation in vitro, but when bound to 
other proteins in RRL, a minor structural difference or interaction with other 
proteins may inhibit the optimal orientation of SMN D7 thus inhibiting 
intermolecular disulfide bond formation.  It would be interesting to determine if 
there is a different sensitivity to disulfide bond formation between SMN WT and 
D7 in vitro, which could discern whether the inability of SMN D7 to form 
disulfide bonds in RRL was due to intrinsic structural differences or extrinsic 
protein interactions.   
3.3.4 Optimization of SMN WT stability   
In order to prevent degradation, protease inhibitors were added to the 
refolding and elution buffers during SMN WT purification.  SMN was purified 
with and without protease inhibitors and analyzed for stability at 4°C.  After one 
day, the SMN WT without protease inhibitor was not present at all and a small 
amount of SMN WT was present in the purification with protease inhibitors 
(3.4b).  Protease inhibitors did increase the stability of SMN slightly, but even 
SMN WT with protease inhibitors either degraded and/or precipitated out of 
solution at 4°C.   
As discussed in Chapter 2, the concentration of Gemin2 promoted protein 
degradation; we also observed the stability of SMN WT upon concentration.  
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Concentrated SMN WT degraded down to a 25kDa band and the trimer band at 
100kDa shifted down to 75kDa (3.4b).  The shift from 100kDa to 75kDa of the 
trimer band corresponds directly to the shift from 34kDa down to 25kDa of the 
SMN WT monomer band and further provides evidence that SMN WT is forming 
disulfide-linked trimers.  Unexpectedly, concentrated SMN WT was more stable 
then dilute SMN WT possibly because it formed SDS-resistant trimers.   
In an attempt to increase SMN WT stability, protein in elution buffer was 
concentrated and buffer exchanged into Tris buffer and HEPES buffer, incubated 
for seven days and analyzed via SDS PAGE.  SMN WT in the elution buffer lane 
migrated as a more intense band at 34kDa and had less degraded protein bands 
then in the Tris and HEPES buffers immediately after buffer exchange (Figure 
3.4c).  After seven days of incubation at 4°C, concentrated SMN WT appeared to 
degrade and/or aggregate in all buffers with SMN in the elution buffer still 
showing the least amount of degradation.  The high salt, BME, or glycerol in the 
elution buffer may facilitate the stabilization of SMN WT.  All three samples 
migrated as SDS-resistant trimer bands initially after concentration, but the Tris 
and HEPES buffer samples migrated as two higher intensity bands around 50kDa, 
which could be disulfide linked SDS-resistant degradation fragments as those 
buffers did not have BME. Similar to the nucleated aggregation during dialysis, 
disulfide linked degraded SMN WT fragments may promote SMN WT to 
aggregate.  The degradation of BME over time may be responsible for the overall 
decrease in SMN stability seen in all three buffers after seven days.  Overall, 
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SMN WT was unstable over a week time span, while the presence of BME and 
protease inhibitors and high salt temporarily increased stability.      
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Figure 3.4- Stability of SMN  
Purified SMN was analyzed via SDS PAGE for stability.  SMN WT and D7 are 
indicated with an arrow and disulfide-linked trimers are indicated with asterisks. 
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(a) SMN WT and D7 were purified with optimized nickel affinity 
chromatography conditions. (b) Dilute SMN WT purified with and without 
protease inhibitors as well as concentrated SMN WT.  Samples were incubated 
for 7 days at 4°C and were analyzed. (c) Purified SMN WT in elution buffer was 
concentrated and buffer exchanged in either elution buffer containing 50mM 
sodium phosphate pH 7.4, 500mM NaCl, 5mM BME, Tris buffer (20mM Tris pH 
8.5, 250mM NaCl), or HEPES buffer (20mM HEPES pH 7.5, 250mM NaCl, 5% 
glycerol). Elution buffer is indicated with an E, Tris buffer with T and HEPES 
buffer with an H.  Concentrated samples were analyzed immediately after 
concentration and 7 days later for stability. 
 
3.3.5 Comparison of the stability of SMN WT and SMN TRX  proteins 
The stability of SMN TRX and WT were compared during and after 
purification to determine which protein was suitable for future SMN-Gemin2 
characterization studies.  SMN TRX and WT were refolded on-column and the 
process was monitored via SDS PAGE.  SMN TRX had a larger elution band then 
SMN WT even though the SMN TRX over-expression band in the lysate was 
significantly less then the SMN WT suggesting that SMN TRX refolded more 
efficiently (Figure 3.4a).  SMN WT was present primarily in the elution fraction 
as the trimer form at 100kDa with a small amount in the monomer form at 34kDa. 
In the elution fractions, SMN TRX migrated as a slight doublet band at 150kDa 
that corresponded to SDS-resistant trimers and a larger aggregate or oligomeric 
band at 250kDa.  SMN WT also migrated as a 34kDa doublet band immediately 
after purification that shifted down to the lower band in the pooled protein.  One 
possibility for the observed doublet bands is that both SMN proteins undergo 
similar degradation. However, the fact that the SMN TRX construct varies so 
drastically from the SMN WT construct makes this possibility less likely.  
Another possibility is that SMN WT and TRX doublet bands are representative of 
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two different protein states that migrate differently in SDS PAGE. Recombinant 
SMN has been previously noted to have unusual migration in SDS PAGE 
(Campanaro 2009).  The cause of the doublet bands in SMN lacking post-
translational modifications is unclear.   In the pooled fraction, a large majority of 
SMN TRX shifted from the 55kDa monomer form to the aggregate or oligomer 
form at 250kDa.  SMN TRX without BME shifted completely to the aggregate 
band whereas in the SMN WT sample only a small amount of protein shifted to 
the aggregate and the majority of the monomer shifted to the trimer state. In both 
the reducing and non-reducing conditions, SMN TRX favored the monomer or 
aggregate form, whereas SMN WT favored the trimer form.  It is possible that 
the12kDa N-terminal TRX tag inhibits the trimer orientation and disulfide bond 
formation.  The observed aggregation of SMN TRX and WT may be caused by 
nonspecific disulfide bond formation and/or strong hydrophobic interactions of 
the predominantly beta sheet SMN protein (Nielsen 2007).  SMN TRX had a 
higher refolding efficiency and total purified protein, but an increase of soluble 
aggregates or oligomers in SDS PAGE relative to SMN WT suggest SMN TRX 
may not be able to form the same oligomeric states as SMN WT. 
 Next, the stability of both proteins after purification was compared.  SMN 
TRX and WT were incubated at RT or 4°C and protein stability was analyzed via 
SDS-PAGE.  Both samples degrade or aggregate at RT after one and slightly after 
four days (3.4b).  According to these results, there is no significant difference in 
the stability of SMN TRX and WT. 
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 Since both proteins were stable over four days, the stability after protein 
concentration was determined.  SMN WT and TRX were concentrated, and buffer 
exchanged in either HEPES or Tris buffers.  Dilute and concentrated samples 
were analyzed for stability.  Concentrated SMN WT appeared to be more stable 
then SMN TRX as indicated by the larger band at 34kDa and both proteins were 
less stable in Tris buffer (3.4c). Because SMN TRX was less stable then SMN 
WT during protein concentration and SMN TRX favored large aggregates over 
the ability to form disulfide trimers, SMN WT protein was used for further in 
vitro studies to characterize the SMN-Gemin2 interaction. 
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Figure 3.5- Stability of SMN WT compared to SMN TRX 
The stability and solubility of SMN WT and TRX were compared under various 
conditions during and after purification. (a) SMN WT and SMN TRX were 
purified using nickel affinity chromatography. Elution fractions as well as pooled 
fractions were analyzed on standard and non-reducing SDS PAGE. Both SMN 
TRX and WT are indicated with arrows.  SDS resistant oligomers are indicated 
with asterisks, a letter W corresponding to WT, T for TRX and A for soluble 
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aggregate and/or large oligomers. (b) SMN TRX and SMN WT were purified by 
dialysis in PBS and were incubated at 4°C and RT for 4 days to determine their 
stability.  (c) SMN TRX and SMN WT in PBS dialysis buffer were buffer 
exchanged and concentrated in elution buffer (50mM sodium phosphate pH 7.4, 
500mM NaCl, 5mM BME) and Tris buffer (20mM Tris pH 8.5, 200mM NaCl, 
5mM BME).  
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Chapter 4 
CHARACTARIZATION OF GEMIN2 AND SMN PROTEINS 
4.1 INTRODUCTION 
The self-association domains of SMN as well as the oligomerization of 
SMN has been studied, but the actual oligomeric state of SMN in vitro and in vivo 
is unknown (Young 2000a, Lorson).  SMN D7 lacks the ability to form high-order 
oligomers in vitro suggesting that oligomerization is important for the function of 
SMN.  Furthermore, the oligomerization defects of SMN missense mutations in 
SMA correlate with the severity of the disease phenotype (Lorson 1998). 
SMA research has largely been focused on understanding the function of 
SMN by using in vivo cell culture or animal models that use a SMA phenotype to 
work backward and uncover the disease-causing molecular event.  The current 
studies clearly show that oligomerization is at least part of the molecular event 
cascade that leads to SMA.  Our lab’s approach was to start with the SMN protein 
at the beginning of the molecular cascade.  We sought to gain a better 
understanding about the oligomerization of SMN WT and SMN D7 with the hope 
that our SMN protein forward approach combined with others SMA phenotype 
backward approach will eventually close in on the specific molecular event that 
causes SMA.  
SMN-Gemin2 complex interactions have been shown to be important for 
the function of SMN in snRNP assembly (Fischer 1997).  Similar to the knockout 
of the smn1 gene in mice, the knock out of gemin2 is embryonically lethal 
suggesting each of their functions is crucial for development.  Gemin2 and SMN 
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protein levels were shown to be co-regulated in mice and SMN co-localized with 
Gemin2 in Hela cells with the highest frequency relative to other SMN-binding 
proteins (Jablonka 2001, Jablonka 2002, Todd 2010). While SMN has been 
shown to associate with a variety of proteins, the interdependence and consistent 
association of SMN and Gemin2 in vivo suggests Gemin2 is important for the 
majority of SMN functions.  We thus chose to characterize the SMN-Gemin2 
interaction to determine if there is a difference between SMN WT and SMN D7 
with the aim of gaining insights into the SMA pathogenesis.  
In this chapter, we characterized the oligomerization states of SMN WT 
and SMN D7 bound to Gemin2 as well as SMN WT and Gemin2 proteins 
individually.  Purified SMN WT and D7, and Gemin2 proteins were characterized 
by size exclusion column (SEC) chromatography and SDS and Native PAGE 
gels.     
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4.2 METHODS 
4.2.1 Native PAGE  
Protein samples were mixed with 2X native page sample buffer (0.01% 
Bromophenol Blue, 200mM Tris pH 8.0, 20% glycerol) with or without BME and 
run on either a 4-20% gradient  or 12% discontinuous Tris/Glycine gel (TGX gels 
Biorad) at 200V on ice until the dye reached the bottom of the gel.  Proteins were 
also run using a McLellan Tris-boric acid continuous gel system.  Briefly, 
samples were mixed by adding one volume of protein sample to two volumes of 
0.5X Loading dye (0.5X McLellan gel buffer, 10% glycerol, 0.01% bromophenol 
blue) on ice. Samples were loaded onto a 6% Tris/boric acid Mclellan gel made 
and run with the same McLellan gel buffer (10mM Tris, 5mM Boric Acid pH 8.7) 
for 200V for 40 minutes on ice. For Blue Native (BN) PAGE gels, samples were 
mixed with 4X Native dye (Invitrogen BN PAGE kit), loaded onto a Bis-Tris 3-
12% gel and run with anode buffer in the outer chamber and light cathode buffer 
in the inner chamber (Invitrogen BN PAGE Kit).  The gel was run for 1hr on ice 
at 100V through the stacking gel and 250V until the dye reached the bottom of the 
gel. All gels were fixed by heating the gel in 100mL of fixing buffer (40% 
methanol, 10% acetic acid) in the microwave for 30 seconds and then gently 
shaking for 20 minutes.  This process was repeated for staining (coomassie blue-R 
stain) and destaining buffers (10% acetic acid) according to the Invitrogen BN 
PAGE staining protocol. 
4.2.2- Size exclusion chromatography 
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A Superdex 200 5/150 analytical size exclusion tricorn column (GE 
healthcare) was run using a Pharmacacia FPLC system and monitored via a 
Biorad Econoview detector coupled to an analogue-digital convertor (Datataq).  
Standards (BSA, Carbonic anhydrase and B-amyalose or blue dextran-1mg/ml) 
and concentrated protein samples (SMN WT, SMN TRX, Gemin2, SMN D7 and 
SMN-G2- concentration range of 0.5-3mg/ml) were run with either phosphate 
SEC buffer (50mM sodium phosphate, 150mM NaCl pH 7.4) or Tris-reducing 
SEC buffer (20mM Tris HCl, pH 8.0, 200mM or 500mM NaCl, 1mM EDTA, 5-
10mM BME) at a flow rate of 0.2ml/min with a detector sensitivity (Biorad 
Econoview) of 0.01auf and an anologue-digital converter frequency of 1s.   
4.2.3- SEC sample preparation 
Frozen protein samples were thawed quickly and immediately 5-10mM 
BME, 1mM EDTA and 1X protease inhibitors (Gold Biochem) were added to 
each protein aliquot.  SMN was bound to Gemin2 by incubating 1:1 molar ratios 
of SMN WT and Gemin2 protein at 4°C for one hour.  Protein samples were then 
concentrated in a 500uL 10kDa molecular weight cut off membrane for 20 
minutes at 4°C. Protein samples were first buffer exchanged into the appropriate 
SEC buffer and then a volume of 25uL was injected onto the column.    
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4.3 RESULTS AND DISCUSSION 
4.3.1 Oligomeric states of SMN in vitro 
 In order to determine the oligomeric state of SMN WT in vitro, purified 
proteins were run on an analytical SEC column that contained a large separation 
range from 20kDa to 600kDa.  SMN WT was first run under standard SEC 
conditions (50mM sodium phosphate pH 7.4, 150mM NaCl).  The SMN WT 
elution peaks run with standard SEC buffer showed three very broad peaks with 
one of those peaks being at the void volume of the column (Figure 4.1a left 
panel).  The three peaks suggest that SMN WT did not form one discrete oligomer 
in vitro; rather SMN WT formed a mixture of oligomers that we have labeled in 
relative size as small, medium and large.  The molecular weights of the most 
prominent peaks were calculated from a set of protein standards and are shown in 
the chromatogram.  The broad peak of each relative oligomeric size suggests that 
SMN WT formed a mixture of states within each size range.  For example, the 
small oligomeric peaks at 47kDa and 79kDa may be a mixture of monomers, 
dimers and trimers that cannot be resolved.  It is possible that resolved peaks were 
not observed due to relatively low protein concentration, low detector sensitivity 
and the self-association of full-length SMN WT with degraded fragments.  
Further SEC experiments using a column with a smaller separation range could be 
used to determine the specific lower molecular weight oligomeric states of SMN 
WT.     
4.3.2 The effects of salt and BME concentration on SMN oligomers  
  73 
Because SMN WT SEC under standard SEC conditions led to persistent 
column clogging and maintenance, alternative buffer conditions with high and 
low salt concentrations were employed.  Varying BME concentrations were 
employed as well, since the SDS-resistant oligomers in Chapter 3 indicated that 
disulfide bond formation may lead to non-specific oligomer formation of SMN.  
SMN WT run on SEC with Tris buffer containing low salt and 7.5mM BME 
resulted in small and medium, but no large oligomeric states at the void volume 
suggesting that BME was in deed able to shift the large oligomeric states by 
reducing disulfide bonds (Figure 4.1a, right panel).  In addition, the more resolved 
peaks at 44kDa and 85kDa point to SMN WT being in a mixture of monomers 
and dimers.   
 SMN WT was next run with SEC buffers containing a range of salt and 
BME concentrations to gain insight into the formation of SMN oligomeric states.  
In agreement with the suggestion that increased BME caused smaller SMN WT 
oligomeric states, none of the buffers containing BME showed large oligomers in 
SEC.  The higher concentrated BME buffers shifted the majority of the medium 
oligomers to small oligomers with the Tris-high salt buffer predominantly 
favoring small oligomers at 44kDa  and no observed peaks at 85kDa (Figure 
4.1b). There also appeared to be a trend of decreased SMN WT small oligomer 
size with increasing salt concentration.  However, more SEC analysis of SMN 
WT containing buffers with the same BME concentration and varying salt 
concentration would need to be done to determine the separate contribution of salt 
and BME concentration to small oligomer formation.  The two resolved peaks in 
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Figure 4.1a (right panel) at 44 and 85kDa were also observed in all buffer 
conditions with the second larger peak having a molecular weight approximately 
double of the first peak.  Upon SDS PAGE analysis, fractions eluted from SEC in 
the small oligomer range migrated at 66kDa, which could be a disulfide-linked 
SMN WT dimer (data not shown). These results provide evidence showing that 
SMN WT in the small oligomers observed in SEC existed at least in monomers 
and dimers.  The SEC molecular weights of SMN WT monomers and dimers of 
44kDa and 88kDa are significantly higher then the actual molecular weights of 
34kDa and 68kDa.  The discrepancies in molecular weight of SMN WT are likely 
due to the increased hydrodynamic size of SMN observed in the SEC of the SMN 
self-association domain (Pellerzzoni 1999, Martin 2012). However, the presence 
of SMN WT dimers is not in agreement with either the SDS-resistant 100kDa 
trimers observed in Chapter 3 or our low-resolution SMN WT hexamer structure.  
Further experiments to determine the actual composition of SMN oligomers and 
the ratio of those oligomers in vitro could provide more insight into the assembly 
and oligomerization of SMN WT in vivo.  We propose that SMN WT forms three 
oligomeric sizes in vitro with the small oligomeric size composed of monomers, 
dimers and/or trimers, the medium size composed of hexamers that we observed 
in our low-resolution structure and the large size composed of two interacting 
hexamers that make up a dodecamer (Figure 4.1c).  
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Figure 4.1- SMN WT oligomerization states 
(a) SMN WT in elution buffer were concentrated and buffer exchanged into SEC 
Tris buffer (20mM Tris pH 8.0) with either low salt (200mM NaCl) or high salt 
(500mM NaCl) and varying concentrations of BME or Phosphate buffer (50mM 
sodium phosphate pH 7.4, 150mM NaCl). Protein samples were run on a 
superdex200 SEC column and eluted protein was detected by absorbance at 
280nm (measured in Volts) every second. Predicted molecular weight (kDa) of 
the protein peaks was calculated based on a set of protein standards.  The left 
panel indicates SMN WT in elution buffer and the right panel indicates SMN WT 
in Tris Buffer with low salt and 7.5mM BME.  Arrows indicate the protein peaks 
and the predicted molecular weight or the void volume of the column.  The 
relative size of the SMN oligomers was categorized into three sizes, small, 
medium and large.  (b) Relative oligomer sizes of SMN WT run on SEC in 
varying buffer conditions.  (c) Proposed model of SMN WT oligomeric states in 
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vitro from SEC results. SMN WT (purple) may form small oligomers of 
monomers, dimers and/or trimers as well as larger hexamers and dodecamers. 
 
4.3.3 Oligomeric state of SMN D7 in vitro 
  The oligomerization state of SMN D7 was examined using SEC with low 
salt buffer containing BME.  Compared to SMN WT that formed both small and 
medium oligomers, SMN D7 only formed an unresolved small oligomer peak 
with a molecular weight of 85kDa (Figure 4.2a).  This is in agreement with 
previous data showing that SMN D7 has a decreased ability to oligomerize in 
vitro (Pellerzzoni 2000).  According to our results, SMN D7 was able to form 
monomers, dimers and/or trimers in vitro (Figure 4.2b).  The dimer or trimer 
formation of SMN D7 was unexpected, as several studies have shown that SMN 
D7 has either partial or no ability to self-associate (Lorson 1998, Pellerzzoni 
1999, Young 2000b).  All three studies contained SMN protein with either an N-
terminal GST or TRX tag.  We have shown in Chapter 3 that the 12kDa N-
terminal TRX tag changed the state of SDS-resistant oligomers observed in SDS 
PAGE suggesting that the N-terminal tag may inhibit SMN WT self-association 
likely at the N-terminal self association site of SMN.  The inhibition of the N-
terminal self-association site by the larger protein tags in these studies could 
explain the lack of self-association observed between SMN WT and SMN D7 
(Figure 4.2c).  Our data showed that SMN D7 can self-associate but does not 
directly prove that SMN WT can self-associate with SMN D7, which is likely to 
occur in most SMA patients with a high ratio of SMN D7 to SMN WT.  Since it 
has been recently shown that the C-terminal region of  SMN D7 alone did not 
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form dimers or trimers, our results indicate that the SMN D7 self-association 
observed is likely due the interaction of the SMN D7 N-terminal self-association 
site and thus we predict that SMN WT and SMN D7 are likely able to self-
associate as well.  However, in vivo, it is likely that SMN WT containing both the 
N-terminal and C-terminal self-association has a higher affinity for SMN WT 
compared to SMN D7.  SEC analysis of our SMN D7 combined with SMN WT in 
a smaller separation range able to resolve monomers to trimers could verify that 
SMN WT and SMN D7 self-associate, which is the opposite of the current view 
of the SMN D7-SMN WT interaction.  Determining if SMN WT-D7 self-
associate in vivo and the functional consequences of the association will be very 
important in understanding the molecular function of SMN.    
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Figure 4.2- SMN D7 oligomerization states 
(a) SMN D7 in elution buffer was concentrated and buffer exchanged into SEC 
buffer (20mM Tris pH 8.0, 200mM NaCl, 7.5 mM BME). Protein samples were 
run on a superdex 200 SEC column and eluted protein was detected by 
absorbance at 280nm (measured in Volts) every second. Predicted molecular 
weight (kDa) of the protein peaks was calculated based on a set of protein 
standards. (b) Proposed oligomeric states of SMN D7 from SEC results (blue).  
(c) Proposed N-terminal self-association of SMN D7 (blue). SMN D7 with a GST 
tag (green) does not self-associate whereas SMN D7 with a histidine tag (orange) 
does self-associate.     
 
In summary, SMN WT formed a mixture of oligomeric states while SMN D7 only 
formed smaller oligomeric states. Surprisingly, under our conditions of low salt 
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and BME, SMN D7 was able to self-associate in a similar manner as SMN WT.  
The current molecular view of the SMN D7-SMN WT interaction is that SMN D7 
cannot self-associate with itself or SMN WT and this lack of self-association is 
responsible for the loss of function of SMN in SMA.  Our data indicates a model 
in which SMN WT and SMN D7 and other missense mutated SMN proteins are 
able to self-associate, but that the self-association interface created by the SMN 
D7 and missense mutated SMN proteins prevents binding of proteins essential for 
function (Figure 4.3a).  The function and the specific protein that binds to the 
SMN self-association interface is currently unknown, but the function likely 
involves a specific step in the assembly of splicing or β-actin RNPs.  In agreement 
with our model, Martin et al showed that several SMN mutant proteins with 
mutations in the C-terminal oligomerization domain do not effect the C-terminal 
self-association of SMN in vitro (Martin 2012).  Our model also explains the 
highly variable SMA phenotypes as the observed phenotype would vary based on 
two factors, the oligomerization interfaces present and the smn2 copy number 
(4.3b).  The oligomerization interfaces of each of three possible combinations of 
SMN, SMNWT-SMN WT, SMN WT-SMN D7 and SMN D7-SMN D7 will be 
referred to from here on as WT-WT, WT-D7, and D7-D7.  The three SMN 
interfaces would have a range of protein binding affinities with the WT-WT 
interface having the highest relative binding affinity to an unknown protein and 
D7-D7 having no binding affinity.  In 95% of SMA patients lacking a functional 
SMN WT protein from the smn1 gene due to a gene deletion in exon 7, the 
predominant interfaces present would be WT-D7 and D7-D7 creating a lower 
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protein binding affinity, which would then inhibit the function of SMN and result 
in the SMA phenotype (Figure 4.3b). The variability seen in SMA phenotype 
severity ranging from mild to severe would result from variability in the copy 
number of the smn2 gene, which would change the ratio of WT-D7 and D7-D7 
oligomer interfaces. For example an additional smn2 copy number expressing 
90% SMN D7 and 10% SMN WT would increase the amount of SMN D7-SMN 
D7 interfaces dramatically as well as some WT-D7  and WT-WT interfaces.  
However, since D7-D7 interfaces have no protein binding, the SMA phenotype 
should be less severe as a slight increase in the WT-D7 interfaces with partial 
protein binding affinity and WT-WT with high protein binding affinity would 
result in higher SMN function.  This is in agreement with the general trend 
observed in SMA phenotypes, in which a higher smn2 copy number correlates to 
a less severe phenotype (Wirth 2006b).  Although there is a general trend relating 
severity (Type I-IV) with smn2 copy number, phenotypic variability also exists 
within each disease type (Wirth 2000b).   In our model this may be accounted for 
by SMA patients that have missense mutations in the C-terminal region of SMN, 
which would likely change the oligomer interface to varying degrees depending 
on the specific mutation as well as whether the mutation was homozygous or 
heterozygous. 
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Figure 4.3- Model of the self-association of SMN in SMA 
(s) SMN is proposed to self-associate in three possible combinations, SMN WT-
SMN WT, SMN WT-SMN D7, and SMN D7-SMN D7 aided by Gemin2 
dimerization (red).  SMN WT is shown in purple and SMN D7 is shown in blue.  
Upon self-association, a new C-terminal self-association interface is created that 
binds an unknown protein with an unknown function.  The relative protein 
binding affinity is high in SMN WT-SMN WT interfaces, low in SMN WT-SMN 
D7 interfaces and abolished in SMN D7-SMN D7 interfaces. (b)  The relationship 
between smn copy number, predicted SMN self-association sites and protein 
binding affinity.       
 
4.3.4 Sensitivity of N45-Gemin2 oligomerization state to salt and reducing agent 
concentration 
 Native Gemin2 has been shown to predominantly form dimers with a 
minor amount of monomers and trimers.  SEC of N45-Gemin2 was performed 
under varying buffer conditions to ascertain if N45-Gemin2 forms similar 
oligomers as native Gemin2.  N45-Gemin2 formed a dimer at 63kDa under Tris-
low salt-7.5mM BME conditions with a minor amount of large oligomers at the 
void volume (Figure 4.4a).  The SEC molecular weight of 63kDa was close to the 
actual molecular weight of 58kDa and the second 56kDa peak observed in SEC is 
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likely the degraded 25kDa N45-Gemin2 observed in SDS PAGE.  Both high salt 
buffer conditions resulted in an array of N45-Gemin2 oligomer states (Figure 
4.4b, c). Although the increased BME and salt concentration abolished the large 
oligomer peak seen in the low salt buffer, it caused the N45-Gemin2 to form a 
range of high-order oligomers. These results may explain the small crystals 
observed in N45-Gemin2 crystallography trials in Chapter 2, in which the protein 
was concentrated in buffer with high concentration of salt and BME.  The fast 
forming microcrystals were likely caused by increased nucleation resulting from 
the increased self-association of N45-Gemin2 in high salt and BME buffer 
conditions.  N45-Gemin2 formed a myriad of oligomerization states under 
varying buffer conditions.  The low concentrated salt and BME buffer condition 
was chosen for SMN-Gemin2 interaction studies because N45-Gemin2 dimers are 
consistent with the dimer formation of native Gemin2 and the void volume 
oligomerization was abolished resulting in less aggregation and SEC column 
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Figure 4.4- Gemin2 oligomerization states 
N45-Gemin2 in elution buffer was concentrated and buffer exchanged into Tris 
buffer (20mM Tris pH 8.0) with either low salt (200mM NaCl) or high salt 
(500mM NaCl) and varying concentrations of BME. Protein samples were run on 
a superdex200 SEC column and eluted protein was detected by absorbance at 
280nm (measured in Volts) every second. Predicted molecular weight (kDa) of 
the protein peaks was calculated based on a set of protein standards.  Arrows 
indicate the protein peaks and the predicted molecular weight or void volume.  
The predicted Gemin2 oligomer(s) are indicated above the peaks. (a) Gemin2 
SEC was run in Tris buffer with low salt and 7.5mM BME.  (b) Gemin2 in Tris 
buffer with high salt and 10mM BME.  (c) Gemin2 in Tris buffer with high salt 
and 5mM BME. 
 
4.3.5 SMN bound to Gemin2 forms large oligomers and/or soluble aggregates 
 SMN WT and TRX were each incubated with or without N45-Gemin2, 
concentrated and analyzed via Native PAGE to verify a SMN-Gemin2 interaction.  
SMN WT, SMN TRX and N45-Gemin2 all three showed bands that migrated at 
the same distance as β-amylase (200kDa) (Figure 4.5a), which were likely large 
oligomers that cannot migrate further into the gel, as SMN TRX is twice the size 
of SMN WT and N45-Gemin2.  SMN WT bound to N45-Gemin2 resulted in an 
intense oligomer band at 200kDa as well as a large amount of oligomer and/or 
aggregate protein in the well of the native PAGE gel.  This suggested that SMN-
Gemin2 forms large oligomers and /or soluble aggregates in vitro. SMN TRX also 
migrated as both the oligomer band at 200kDa as well as in the well, but the 
larger oligomer/aggregate was more prevalent.  The native PAGE results indicate 
that both SMN WT and SMN TRX interact with Gemin2; however, it was 
difficult to draw any conclusions about the details of the interaction and the 
oligomers from this data because the control protein oligomers migrate at the 
same distance as the SMN-Gemin2 oligomers.  Furthermore, SMN-Gemin2 was 
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more concentrated as some SMN WT and SMN TRX aggregated during 
concentration.  
 To gain further insight into the SMN-Gemin2 interaction, SMN WT was 
bound to N45-Gemin2 and run on SEC.  SMN WT and Gemin2 alone were run on 
SEC as controls.  SMN-Gemin2 eluted from the column as large oligomers or 
soluble aggregates at the void volume as well as at the same elution time as SMN 
WT and Gemin2 (Figure 4.5b).  SEC of SMN-Gemin2 did not result in a discrete 
peak, but instead resulted in a broad peak at the void volume, suggesting SMN-
Gemin2 formed an oligomer that is larger then 600kDa or a variety of unresolved 
large oligomers similar to SMN WT.  SMN WT-Gemin2 formed large oligomers, 
which prevented the characterization of the SMN-Gemin2 interaction 
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Figure 4.5- The oligomerization state of SMN bound to Gemin2.  
(a) Gemin2, SMN WT and SMN TRX alone or combined were concentrated and 
run on a 4-20% Native Tris gel.  The asterisks indicate protein bands with the 
corresponding letter indicating the protein (G-Gemin2, W-SMN WT, T-SMN 
TRX, Olig-oligomer).  200kDa and 66kDa indicate the migration distance of b-
amylase and BSA in native page. (b) SEC of SMN WT (blue), Gemin2 (pink), 
and SMN WT + Gemin2 (orange) buffer exchanged in and run with 50mM 
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sodium phosphate pH 7.4, 150mM NaCl.  Arrow indicates the oligomers which 
eluted at the void volume.     
   
4.3.6 The SMN/Gemin2 complex is sensitive to disulfide bond formation 
We have previously shown that disulfide bonds may be important for 
SMN WT oligomer formation in Chapter 3.  Since, the SMN-Gemin2 complex 
forms similar large and possibly even varying oligomeric states as SMN WT 
does, we next sought out to determine if SMN-Gemin2 oligomers in vitro were 
mediated by disulfide bond formation.  SMN WT bound to Gemin2 and 
concentrated in elution buffer (S +G Elut) as well as SMN WT-Gemin2 
previously concentrated in Tris buffer (S+G old) were both run on a SDS PAGE 
gel under reducing and non-reducing conditions.  The SMN WT-Gemin2 in Tris 
buffer under non-reducing conditions completely shifted up to a molecular weight 
around 200kDa, whereas in the freshly prepared SMN WT-Gemin2, the SMN WT  
shifted up to a smear at 200kDa, but the Gemin2 did not (Figure 4.6a).  This 
indicates that the SMN WT-Gemin2 interaction in the old sample was linked via 
disulfide bonds most likely induced by the gradual degradation of BME in the 
buffer.  Another interesting point is that the degraded protein bands migrated with 
the oligomer at 200kDa in the old SMN WT-Gemin2 sample, whereas the smaller 
degradation bands in the freshly prepared SMN WT-Gemin2 sample did not.  
This suggested that buffer conditions without BME promoted non-specific 
disulfide bonds between full-length and degraded SMN WT proteins.  The 
determination of non-specific disulfide bonds was important because the 
degradation of SMN WT and Gemin2 cannot be fully inhibited even in the 
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presence of protease inhibitors.  Furthermore, in the non-reducing SMN WT-
Gemin2 sample that was not boiled during sample preparation, the majority of 
SMN WT shifted primarily up to the 100kDa oligomer band observed in Chapter 
3 instead of the large 200kDa oligomer when the sample was boiled.  Either SMN 
WT forms a larger oligomer made up of the small 100kDa oligomers that is 
strongly associated and cannot be dissociated by SDS unless heat is applied or 
SMN WT 100kDa oligomers aggregate in the presence of SDS and heat.  The 
later is less likely because the protein was able to enter the gel, suggesting it was 
soluble.   
 To further assess the role of disulfide bonds in SMN-Gemin2 complex 
formation, SMN WT and N45-Gemin2 were mixed at three different molar ratios 
(1:1, 1:3, and 3:1) and run on a SDS PAGE gel.  The presence of the higher 
100kDa oligomeric SMN WT band decreased as N45-Gemin2 increased in molar 
ratio relative to SMN WT (Figure 4.6b).  This provided evidence that a structural 
change occurred upon SMN WT binding to Gemin2 that prevented the disulfide 
bond formation of SMN WT 100kDa oligomers.  In addition, because the 
intensity of the full-length SMN WT and Gemin2 bands in the monomer form 
were calculated to be present at a 1:1 ratio with the excess SMN WT in the 
100kDa form (data not shown), SMN WT and Gemin2 likely bind at a 1:1 ratio.   
 Similar to SMN WT, the SMN-Gemin2 interaction is sensitive to disulfide 
bond formation.  SMN WT may undergo a change in structural confirmation 
and/or oligomerization state upon binding to Gemin2.                  
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Figure 4.6- Sensitivity of the SMN-G2 complex to disulfide bond formation. 
(a)  SMN WT was mixed with Gemin2 at equal molar ratios and concentrated in 
elution buffer after purification (S+ Elut).  SMN WT and Gemin2 were mixed at 
equal molar ratios and buffer exchanged into 20mM Tris pH 8.0, 200mM NaCl, 
5mM BME and incubated at 4°C for several weeks (S+G old).  All samples were 
run on an SDS PAGE gel with (reducing) or without (non-reducing) BME in the 
loading dye.  The last sample was not boiled.  (b)  SMN WT and Gemin2 were 
mixed at 1:1, 1:3 and 3:1 ratios and concentrated.  All S+G samples along with 
SMN WT (S) and Gemin2 (G) alone were run on an SDS PAGE gel.  For both 
gels, arrows indicate SMN WT and Gemin2 and asterisks indicate oligomers of 
either SMN WT (S*) or SMN-G2(S+G*).   
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4.3.7 Comparison of the SMN-Gemin2 interaction between SMN WT and SMN D7 
SMN D7 and SMN WT bound to N45-Gemin2 were run on SEC to 
determine if the SMN-Gemin2 interaction is different between SMN WT and the 
SMN D7.  SMN WT-Gemin2 showed two major peaks at 140kDa and at the void 
volume (Figure 4.7a).  The 140 kDa peak was consistent with the addition of the 
SMN WT peak and the Gemin2 peak and based on the predicted dimer state of 
Gemin2 and the proposed dimer state of SMN WT, it was likely a heterodimer of 
two SMN proteins and two Gemin2 proteins.  SMN D7-Gemin2 unexpectedly 
formed heterodimers and larger oligomers, although the ratio of the heterodimer 
peak to the oligomer peaks was higher when compared to SMN WT (Figure 
4.7b).   A SMN D7-Gemin2 peak of 91kDa was also observed.  This 91kDa peak 
was slightly larger then the SMN D7 only control of 85kDa.  With the resolution 
of the SEC chromatogram, it is unclear if the 91kDa peak was SMN D7 or 
another oligomeric state of SMN-Gemin2.   
SMN D7 bound to Gemin2 formed similar oligomeric states as SMN WT 
bound Gemin2, but the equilibrium of the states were different as SMN WT-
Gmin2 favored higher-order oligomers and SMN D7-Gemin2 favored the 
formation of a heterodimer.   
 SDS PAGE of the input SEC protein samples was run to verify the purity 
and ratio of SMN and Gemin2 proteins.  All SMN WT-Gemin2 SEC samples 
migrated as monomers in SDS PAGE (Figure 4.7c).  The SMN D7 in the protein 
only control sample migrated as 100kDa oligomers whereas half of the SMN D7 
in the SMN D7-Gemin2 sample migrated as 100kDa oligomers.  The SDS PAGE 
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gel suggested that SMN D7 in the SMN D7-Gemin2 sample existed in two 
oligomeric states.  Again, it is difficult to draw firm conclusions without 
identification of the proteins that eluted from column.  However, the second 
oligomeric state of SMN D7 that migrated at 100kDa on the SDS PAGE gel may 
correspond to the additional 91kDa peak observed in the SEC chromatogram of 
SMN D7-Gemin2.  If this was, indeed true, it suggests that disulfide-linked SMN 
D7 was inhibited from binding Gemin2.  Further experiments to duplicate these 
results would need to be done for verification followed by the exploration of the 
disulfide bond sensitivity difference between SMN WT and D7 and the effect on 
Gemin2 binding.  SMN WT and Gemin2 concentrated down to a 1:1 ratio that 
was more concentrated then SMN WT supporting the 1:1 binding ratio and higher 
stability of SMN WT-Gemin2.  SMN D7 and Gemin2 did not concentrate down 
to a 1:1 ratio, which could be due to either inefficient binding of SMN D7 to 
Gemin2 or insufficient full-length SMN D7 as SMN D7 on SDS PAGE also 
showed a degradation product at 25kDa.   
 SMN WT and SMN D7 both bound Gemin2 at a 1:1 ratio suggesting that 
SMN-Gemin2 binding alone does not lead to SMA.  In accordance with our 
results that insufficient Gemin2 binding does not cause the SMA phenotype, a 
SMA missense mutation D44V, located in the Gemin2 binding domain of SMN, 
was originally shown to disrupt Gemin2-SMN binding in vitro, but recently 
Sarachan et al discovered the disruption in Gemin2 binding was facilitated by 
detergent in the experimental system (Sarachan 2012).  SMN D7 bound to 
Gemin2, but did not form higher-order oligomers like SMN WT.  Our data 
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indicated SMN WT-Gemin2 oligomers are predominantly facilitated by the 
oligomerization of SMN WT while Gemin2 enhances oligomerization, as SMN 
D7 did not form higher-order oligomers unless it was bound to Gemin2.    
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Figure 4.7- Comparison of the Gemin2-SMN interaction between SMN WT and 
D7. 
(a) SMN WT and D7 were each mixed with equal molar ratios of Gemin2 and 
buffer exchanged into Tris buffer (20mM Tris pH 8.0, 200mM NaCl, 7.5mM 
BME).  Protein samples were run on a superdex 200 SEC column and eluted 
protein was detected by absorbance at 280nm (measured in Volts) every second. 
Predicted molecular weight (kDa) of the protein peaks was calculated based on a 
set of protein standards.  The chromatogram of SMN WT alone (blue) alone, 
Gemin2 alone (pink) and SMN WT/Gemin2 (orange) with arrows indicating the 
peaks of SMN-Gemin2 and asterisks indicating peaks of SMN WT and Gemin2 
protein controls.  The predicted SMN/Gemin2 oligomers are indicated above the 
peaks.  (b) The SEC chromatogram of SMN D7 (blue) alone, Gemin2 (pink 
alone) and SMN D7/Gemin2 (orange) with arrows indicating the peaks of SMN-
Gemin2 and asterisks indicating peaks of SMN D7 and Gemin2 protein controls. 
(c) SDS PAGE analysis of the input protein samples loaded onto the SEC column. 
Arrows indicate SMN WT-Gemin2 and asterisks indicate oligomers of SMN (S*).  
(d) The predicted model of SMN-Gemin2 oligomers from SEC results.  SMN-
Gemin2 form heterodimers and large oligomers composed of heterodimers 
subunits.  
 
We propose a model of the oligomerization of SMN-Gemin2 in the SMA 
disease.   The first part of the model predicts the equilibrium of SMN-Gemin2 
oligomers arising from the mixture of SMN WT and SMN D7 (Figure 4.7d).  The 
equilibrium is between the two SMN-Gemin2 states we observed in SEC, 
heterodimers and the large oligomers.  As discussed in Section 4.3.3 the mixture 
of SMN WT and SMN D7 in vivo likely leads to three possible combinations of 
the self-association of SMN, WT- WT, WT-D7 and D7-D7.  We predict that WT-
WT favors SMN-Gemin2 large oligomers, WT-D7 favors an equal mixture of 
large oligomers and heterodimers, and D7-D7 favors heterodimers.  We predict 
that the large oligomers and heterodimers of SMN-Gemin2 each have a specific 
function.  In deed, it has been shown in vitro that only higher-order oligomers of 
SMN WT bound to SmB protein suggesting a function in snRNP assembly or 
sequestration and storage of RNP proteins (Pellerzzoni 1999).  The function(s) of 
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the heterodimer is unknown, but the assembly of the SMN complex is likely to be 
one of these functions as it is unlikely that all the proteins in the SMN complex 
would be able to bind to SMN-Gemin2 large oligomers.  Assuming that each WT- 
WT, WT-D7 or D7-D7 correlate to a specific equilibrium of large oligomers and 
heterodimers and each of those oligomeric states have a specific function, the 
amount of SMN WT and D7 produced from the smn1 and smn2 genes would 
modulate those two functions.  The last part of the model is to correlate SMN-
Gemin2 oligomerization modulation to the SMA phenotype.  To do this, we 
estimated the three combinations of SMN WT and D7 in individuals that are 
healthy, SMA carriers, and SMA patients.  These approximations were based on 
observed relative smn gene copies as well as the higher affinity WT-WT versus 
WT-D7 self-associations (Young 2000b, Diep Tran 2001, Kao 2006).  Healthy 
individuals with two of each smn gene copy are predicted to have WT-WT SMN-
Gemin2 large oligomers, D7-D7 SMN-Gemin2 heterodimers and some WT-D7 
SMN-Gemin2 containing both oligomeric forms.   SMA carriers are predicted to 
have WT- WT SMN-Gemin2 large oligomers and slightly more WT-D7 and D7-
D7 heterodimers as they have more copies of smn2.  SMA patients are predicted 
to have a majority of D7-D7 and D7-WT SMN-Gemin2 heterodimers because 
they predominantly have SMN D7 being produced from the smn2 gene. We 
predict that healthy individuals and SMA carriers do not show a 
neurodegenerative phenotype because they have enough WT-WT SMN Gemin2 
to form large oligomers and perform the function associated with those oligomers, 
whereas SMA patients with SMN D7 only form SMN-Gemin2 heterodimers and 
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therefore lose the large oligomer function.  One interesting observation in 
agreement with this model is several recent genetic studies correlating the 
prevalence of neurodegenerative diseases with smn gene copy numbers.  These 
studies showed that individuals with either a homozygous deletion of smn2 or a 
lower ratio of smn2 copies relative to smn1 copies have a higher incidence of 
sporadic lower motor degradation (LMD) disease and sporadic amytrophic lateral 
sclerosis (ALS) (Blauw 2012, Lee 2012, Kim 2010, Corcia 2009).  In our model, 
the higher smn2:smn1 gene copy ratio of these LMD and ALS patients would 
results in a more WT-WT SMN.  The increased amounts of WT-WT SMN 
interfaces would then lead to an equilibrium shift to SMN-Gemin2 large 
oligomers and a neurodegenerative phenotype by limiting or abolishing the 
function of the SMN-Gemin2 heterodimers.  Only 10-14% of the population was 
projected to have homozygous deletions of the smn2 gene, which was 
significantly higher then the projected incidence of ALS and LMD in individuals 
lacking the smn2 gene (Workman 2009).  However, these initial genetic studies 
had a small population size and more genetic studies would give more insight into 
the correlation between smn copy number and neurodegenerative diseases.  This 
model is a simplified explanation of the effects of SMN-Gemin2 oligomerization 
in SMA. Also of note, is that the SMN-Gemin2 oligomerization modulation 
model is partially exclusive from the SMN self-association model presented in 
Section 4.3.3.  The SMN self-association model is based on the assumption that 
SMN D7-D7 self-association interfaces do not have protein binding affinity and 
therefore a loss of function occurs.  However, the SMN-Gemin2 oligomerization 
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modulation model is based on the assumption that each oligomeric state of SMN-
Gemin2 has a specific function.  We currently do not know whether one or 
several functions of SMN lead to the neurodegenerative SMA phenotype in motor 
neurons and not other cell types.  Research on the functions SMN and SMN-
Gemin2 oligomers including the mixture of SMN WT and SMN D7 will lead to a 
better understanding of the molecular mechanism of SMA as well as providing 
specific drug targets to speed up the SMA drug discovery process.     
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Chapter 5 
CONCLUSION 
5.1 CONCLUSION 
 SMA is a fatal neurodegenerative disease caused by low levels of SMN 
WT protein, which currently does not have a treatment.  We determined that SMN 
WT forms a mixture of oligomers whereas SMN D7 does not.  We characterized 
the interaction of SMN-Gemin2 and found that the proteins associated with a 1:1 
ratio. SMN D7 was unexpectedly able to self-associate in vitro, which was 
enhanced upon binding to Gemin2.  We predict two models that link both SMN 
self-association interfaces and SMN-Gemin2 oligomerization to the SMA disease.     
5.2 FUTURE WORK 
The future work of this project would be to continue the in vitro characterization 
of SMN oligomerization and the SMN-Gemin2 interaction as well as reproducing 
the SMN-Gemin2 interaction results and verifying the peaks of the SEC 
chromatogram via western blot analysis.  An understanding of the specific 
oligomeric states would optimize the experimental system and further allow for 
the characterization of SMA mutant proteins as well as mixtures of SMN mutant, 
SMN D7 and SMN D7 proteins, which more closely resembles the molecular 
environment of SMA in vivo.  Another important future work is to model the 
SMN-Gemin2 interaction using our low-resolution structures of SMN WT and 
D7, the published Gemin2 structure, and our results about the Gemin2-SMN 
interaction. 
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